On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the Fourth Universal Definition of Myocardial Infarction, which classifies AMI into five types based on pathophysiology. Type 1 is spontaneous MI due to plaque rupture or erosion; Type 2 results from supply-demand imbalance (e.g., anemia, tachycardia); Type 3 is sudden cardiac death; Type 4 is related to (PCI); and Type 5 is related to coronary artery bypass grafting (CABG).
- •Distinguish between and based on the initial electrocardiogram (ECG). STEMI requires immediate reperfusion due to transmural ischemia, while NSTEMI involves subendocardial ischemia and is managed with urgent or early invasive strategies depending on risk stratification.
- •Recognize the significance of (CS), the most lethal complication of AMI. It is characterized by systemic hypoperfusion due to cardiac pump failure and is staged from A (at risk) to E (extremis) using the SCAI classification system.
- •Identify non-atherosclerotic causes of MI, particularly in younger patients and women. (SCAD) is the leading cause of pregnancy-associated MI, while (Myocardial Infarction with Non-Obstructed Coronary Arteries) occurs in 5-10% of cases and requires specialized imaging like Cardiac MRI for diagnosis.
- •Appreciate the time-dependent nature of myocardial necrosis. The "progressive phase" of active necrosis begins at symptom onset, making the "door-to-balloon" time (target < 90 minutes) the most critical metric for improving survival in obstructive cases.
Evaluation
- •Suspect AMI in any patient presenting with acute chest pain, pressure, or discomfort, particularly if it radiates to the left arm, neck, or jaw. Be vigilant for atypical presentations in women, the elderly, and patients with diabetes, who may present with isolated dyspnea, nausea, or epigastric pain.
- •Obtain a 12-lead ECG within 10 minutes of first medical contact. Look for persistent ST-segment elevation in two contiguous leads (≥1 mm in most leads, or age/sex-specific thresholds in V2-V3) to diagnose STEMI.
- •Identify "Occlusion Myocardial Infarction" (OMI) patterns that may not meet formal STEMI criteria but indicate acute occlusion. These include de Winter T-waves (upsloping ST-depression with tall, symmetric T-waves), hyperacute T-waves, and Wellens' syndrome (biphasic or deeply inverted T-waves in V2-V3).
- •Order high-sensitivity cardiac troponin (hs-cTn) immediately at presentation (H0). Utilize the H0/H1 or H0/H2 rapid rule-out/rule-in algorithms; a very low H0 value in a patient symptomatic for >3 hours can often rule out AMI, while a significant absolute delta (change) at 1 or 2 hours suggests acute injury.
- •Perform a targeted physical examination to assess for hemodynamic stability and complications. Use the Killip classification: Class I (no heart failure), Class II (rales, S3 gallop), Class III (pulmonary edema), and Class IV ( with hypotension and hypoperfusion).
- •Rule out life-threatening mimics using the "Triple Rule Out" approach if the diagnosis is ambiguous. Consider (tearing pain, BP discrepancy), (pleuritic pain, tachycardia), and tension pneumothorax.
- •Calculate the GRACE or TIMI risk score to guide the urgency of intervention in NSTEMI. High-risk features (GRACE >140, dynamic ST changes) warrant an early invasive strategy within 24 hours.
- •Utilize point-of-care to identify regional wall motion abnormalities, which support the diagnosis of AMI and help exclude mechanical complications like papillary muscle rupture or ventricular septal defects.
- •Screen for metabolic mimics such as severe , which can produce "pseudo-infarction" ST-elevation patterns on ECG, especially in patients with known renal failure.
- •Consider Cardiac Magnetic Resonance (CMR) imaging within 7-14 days for patients with suspected . CMR is the gold standard for differentiating MI from or by identifying specific patterns of late gadolinium enhancement (LGE).
Management
- •Administer Aspirin 324 mg (chewed) immediately to all patients with suspected ACS unless a true allergy exists. This provides rapid platelet inhibition and is a cornerstone of early therapy.
- •Initiate a second antiplatelet agent (P2Y12 inhibitor) as soon as possible. For STEMI or high-risk NSTEMI, preferred agents include Ticagrelor 180 mg loading dose followed by 90 mg BID, or Prasugrel 60 mg loading dose (only if coronary anatomy is known and no history of stroke/TIA).
- •Provide anticoagulation with Unfractionated Heparin (UFH) 60 U/kg bolus (max 4000 U) followed by 12 U/kg/hr infusion, or Enoxaparin 1 mg/kg SC BID. UFH is preferred if the patient is proceeding immediately to the cath lab.
- •Activate the cardiac catheterization laboratory immediately for any patient with STEMI. The goal is primary PCI with a door-to-balloon time of < 90 minutes at PCI-capable centers or < 120 minutes if transfer is required.
- •Administer Fibrinolytic therapy (e.g., Tenecteplase weight-based bolus) only if primary PCI cannot be performed within 120 minutes of diagnosis and there are no contraindications (e.g., recent intracranial hemorrhage, active bleeding).
- •Restrict supplemental oxygen to patients with SaO2 < 90% or PaO2 < 60 mmHg. Routine oxygen in normoxic patients may cause coronary vasoconstriction and increase infarct size.
- •Manage ischemic pain with Sublingual Nitroglycerin 0.4 mg every 5 minutes (up to 3 doses). Avoid nitrates in patients with right ventricular infarction (leads V3R/V4R elevation) or recent phosphodiesterase inhibitor use (e.g., sildenafil).
- •Stabilize by maintaining a Mean Arterial Pressure (MAP) ≥ 65 mmHg. Use Norepinephrine 0.05–1.0 µg/kg/min as the first-line vasopressor; add Dobutamine 2.5–20 µg/kg/min if hypoperfusion persists despite adequate MAP.
- •Consider early mechanical circulatory support (MCS) with a microaxial flow pump (e.g., Impella) in patients with refractory cardiogenic shock (SCAI Stage D/E) to provide left ventricular unloading.
- •Initiate high-intensity (e.g., Atorvastatin 80 mg daily) as soon as possible, regardless of baseline LDL levels, for their pleiotropic plaque-stabilizing effects.
- •Start an ACE inhibitor (e.g., Lisinopril 5 mg daily) within 24 hours in patients with LVEF < 40%, hypertension, or diabetes, provided they are hemodynamically stable without hypotension.
- •Administer oral Beta-blockers (e.g., Metoprolol succinate 25-50 mg daily) within the first 24 hours only in stable patients. Avoid in those with signs of heart failure, low output states, or risk of cardiogenic shock.
- •Prescribe Mineralocorticoid Receptor Antagonists (MRA) like Eplerenone 25 mg daily for patients already on ACEi and Beta-blockers who have an LVEF ≤ 40% and either symptomatic heart failure or diabetes.
- •Refer all AMI survivors to a formal cardiac rehabilitation program. Participation significantly reduces all-cause mortality and improves functional capacity post-discharge.
- •Discharge criteria include hemodynamic stability for 24-48 hours, successful revascularization, absence of high-grade arrhythmias, and a clear plan for dual antiplatelet therapy (DAPT) adherence, typically for 12 months.
Board Review — High Yield
- •Type 2 MI — Myocardial injury due to supply-demand mismatch (e.g., sepsis, anemia) rather than primary plaque rupture.
- •Killip Class IV — Represents cardiogenic shock; the highest mortality risk category in AMI.
- •de Winter T-waves — Upsloping ST-depression with tall, peaked T-waves in precordial leads; signifies acute LAD occlusion.
- •SCAD — Spontaneous Coronary Artery Dissection; the most common cause of MI in pregnant and postpartum women.
- •S1Q3T3 — Classic but non-specific ECG finding for pulmonary embolism, a major differential for AMI.
- •H0/H1 Protocol — Use of high-sensitivity troponin at 0 and 1 hour to rapidly rule out (low delta) or rule in (high delta) AMI.
- •Right Ventricular Infarct — Suspect with inferior MI + ST-elevation in V4R; treat with fluids, avoid nitrates/diuretics.
- •Dressler Syndrome — Post-MI pericarditis occurring weeks later; autoimmune-mediated, treated with NSAIDs/Colchicine.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸AMI is defined by myocardial necrosis with at least one hs-cTn value above the 99th percentile URL.
- ▸STAMI is a newly recognized overlap phenotype of Superimposed Takotsubo and Acute Myocardial Infarction.
- ▸STEMI and NSTEMI are the primary ECG-based classifications, with STEMI typically requiring more urgent revascularization.
- ▸Inflammatory markers like IL-6 and CRP are critical in determining the severity and long-term prognosis of AMI.
- ▸Non-chest pain (NCP) presentations of STEMI occur and are associated with different demographic profiles and potentially worse outcomes.
- ▸Advanced imaging and AI-based models are now used to quantify infarct size and microvascular obstruction (MVO) heterogeneity.
Definition and Core Pathophysiology
Acute Myocardial Infarction (AMI) is defined as myocardial necrosis resulting from acute ischemia [174]. The clinical diagnosis is established by the detection of a rise and/or fall of cardiac biomarkers, preferably high-sensitivity cardiac troponin (hs-cTn), with at least one value above the 99th percentile upper reference limit (URL), accompanied by clinical evidence of ischemia [172]. This evidence may include symptoms of ischemia, new ischemic electrocardiographic (ECG) changes, or imaging evidence of new loss of viable myocardium [172][182]. Recent evidence emphasizes that AMI is not merely a localized vascular event but a systemic inflammatory process; biomarkers such as Interleukin-6 (IL-6) drive ischemia-reperfusion injury, and their inhibition is currently being explored to reduce myocardial damage [174].
Synonyms and Emerging Phenotypes
While traditionally referred to as a "heart attack," AMI encompasses several distinct clinical phenotypes. A newly recognized entity is STAMI (Superimposed Takotsubo and Acute Myocardial Infarction), an overlap syndrome where AMI and Takotsubo syndrome (TTS) coexist [175]. In a pooled analysis, STAMI patients had a mean age of 67 years, were predominantly female (69%), and presented as STEMI in 57% of cases [175]. This challenges the traditional view of TTS as a diagnosis of exclusion requiring the absence of obstructive coronary disease [175].
Clinical Classification by ECG Presentation
AMI is primarily classified based on the initial electrocardiographic presentation, which dictates immediate management strategies:
- ST-Elevation Myocardial Infarction (STEMI): Characterized by persistent ST-segment elevation, typically indicating complete coronary occlusion [174][181]. STEMI requires rapid revascularization, often coordinated through interhospital transfer calls that can now be summarized using Large Language Models (LLMs) to improve data accessibility [181].
- Non-ST-Elevation Myocardial Infarction (NSTEMI): Characterized by myocardial necrosis without persistent ST-elevation [174]. NSTEMI often occurs in patients with complex comorbidities; for instance, severe obesity (BMI ≥35 kg/m²) combined with high inflammation (CRP >2 mg/L) significantly increases 10-year all-cause mortality in critically ill NSTEMI patients [179]C.
Diagnostic and Risk Stratification Models
Modern classification relies on rapid algorithms and scoring systems to triage patients:
- 0/2-Hour Algorithm: A point-of-care (POC) hs-cTnI algorithm allows for rapid rule-out or rule-in of MI within two hours in the Emergency Department [172].
- SCARE Score: A clinical tool used by emergency medical communication centers to discriminate AMI in patients calling with non-traumatic chest pain [173].
- ASCVD Risk Models: Traditional models like the Framingham Risk Score (FRS) and ACC/AHA ASCVD 2013 are used to predict risk, though their performance varies in specific populations such as South Asians [176].
- SYNTAX Score: Quantifies the complexity of coronary anatomy, which can be predicted non-invasively using the serum biomarker LRG1 combined with LDL-C [183].
Complications and Quality of Life
Classification also extends to the presence of complications and the psychological impact of the event. Pericardial effusion (PE) is a notable complication in young AMI patients (<45 years), and the NT-proBNP/albumin ratio has emerged as a sensitive predictor for this condition [180]. Furthermore, AMI significantly impairs health-related quality of life (HRQoL). Depressive symptoms, measured by the HAM-D scale, are common post-infarction and correlate with worse functional outcomes [177][188]. Younger and middle-aged women (<60 years) report a high psychological and psychosocial burden during long-term follow-up [190].
| Biomarker/Index | Clinical Utility | Key Thresholds/Findings |
|---|---|---|
| hs-cTnI (POC) | Rapid 0/2-hour triage | 99th percentile URL for diagnosis [172] |
| IL-6 | Inflammatory damage marker | Target for tocilizumab therapy [174] |
| NT-proBNP/ALB | Predicts pericardial effusion | Useful in patients <45 years [180] |
| HGI | Glycation index in NSTEMI | Higher HGI associated with better survival [186] |
| AMR & HbA1c | Microvascular resistance | Jointly predict MACCE in diabetic STEMI [178] |
| LRG1 | Coronary complexity | Predicts high SYNTAX score [183] |
Etiology and Triggering Factors
- ▸Low-attenuation plaque (LAP) burden is a stronger predictor of MI than coronary stenosis.
- ▸JAK2 V617F mutations are specifically associated with plaque erosion rather than rupture.
- ▸SCAD-related STEMI carries a higher inpatient mortality risk than atherosclerotic STEMI in contemporary US cohorts.
- ▸AI-guided quantitative CT (AI-QCT) can identify patients who derive the most benefit from lipid-lowering medications.
- ▸Obstructive sleep apnea and nocturnal hypoxemia shift the circadian rhythm of MI onset toward the nighttime.
Atherosclerotic Plaque Morphology and Composition
Acute myocardial infarction (AMI) is primarily driven by the progression and instability of coronary atherosclerotic plaques. Recent evidence from the SCOT-HEART trial indicates that quantitative plaque burden, particularly low-attenuation plaque (LAP), is a superior predictor of fatal or nonfatal MI compared to traditional stenosis assessment [34]. Radiomic phenotypes of these plaques further enhance risk stratification by characterizing complex morphology beyond simple volume [34]. The ISCHEMIA trial confirmed that total plaque volume and composition, quantified via AI-guided quantitative computed tomography (AI-QCT), are independent prognosticators of cardiovascular death or MI [35].
Specific high-risk features identified by optical coherence tomography (OCT) include thin-cap fibroatheroma (TCFA), a minimum luminal area <3.5 mm², a lipid arc >180°, and the presence of macrophages [58]D. The CLIMA study demonstrated that these features significantly impact long-term outcomes over a 5-year follow-up [58]D. Furthermore, the burden of atherosclerosis, as measured by the Gensini score, independently predicts cardiac events, including MI and target vessel revascularization [202]. Plaque calcification also plays a role; regional levels of matrix Gla protein (MGP) and specific MGP polymorphisms are associated with plaque calcification and adverse clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients [193].
Metabolic and Genetic Drivers
Diabetes mellitus significantly alters plaque characteristics, leading to higher coronary artery calcium (CAC) scores and increased quantitative plaque burdens (calcified, non-calcified, and low attenuation) compared to non-diabetic patients, thereby worsening long-term outcomes [33].
Genetic factors are increasingly recognized as etiologic drivers. Clonal hematopoiesis of indeterminate potential (CHIP), specifically mutations with a variant allele frequency (VAF) >0.5%, is associated with major adverse cardiovascular events (MACE) and specific culprit lesion phenotypes in STEMI [54]D. The JAK2 V617F variant is particularly potent, substantially elevating MI risk; it is specifically linked to plaque erosion rather than rupture, a process potentially mediated by neutrophil activation [198]. In East Asian populations, RNF213 variants have been identified as genetic risk factors for vasospastic angina and fatal MI [199].
Spontaneous Coronary Artery Dissection (SCAD)
SCAD is a critical non-atherosclerotic cause of AMI, particularly in younger patients and women [31][45]C. While often involving the right coronary artery or septal branches, left main (LM) SCAD represents a rare but life-threatening presentation, occurring in a cohort where 80% are women with a mean age of 40 ± 11 years [31]. Diagnosis often requires advanced imaging such as OCT or intravascular ultrasound (IVUS) to visualize the false lumen, as standard angiography may only show moderate stenosis [45]C[46]C.
Patients presenting with STEMI secondary to SCAD face higher inpatient mortality, prolonged hospitalizations, and increased costs compared to non-SCAD STEMI patients [197]. The presence of cardiogenic shock in SCAD patients further worsens prognosis; these patients are more likely to be male and have a higher incidence of multi-vessel involvement compared to SCAD patients without shock [201]. Despite its severity, traditional cardiac rehabilitation uptake remains a challenge for SCAD survivors due to perceived lack of relevance or specialized protocols [200].
Inflammatory and Circadian Triggers
Residual inflammation remains a key therapeutic target. The lectin-like oxidized LDL receptor-1 (LOX-1) promotes atherosclerosis by scavenging oxidized LDL; however, phase 2 trials of LOX-1 inhibitors (MEDI6570) did not significantly reduce noncalcified plaque volume in the most diseased segments despite the biological rationale [32].
External triggers and physiological rhythms also influence MI onset. Obstructive sleep apnea (OSA) and nocturnal hypoxemia are significantly associated with the circadian rhythm of MI, specifically increasing the likelihood of MI onset during the night [195]. Additionally, periprocedural myocardial infarction (PMI) in NSTE-ACS patients can be predicted by pre-existing plaque features quantified by CCTA, such as lipid core volume [196].
| Feature | Threshold/Definition | Prognostic Impact |
|---|---|---|
| Thin-Cap Fibroatheroma (TCFA) | Fibrous cap thickness <65 μm | High risk for rupture [58]D |
| Minimum Luminal Area (MLA) | <3.5 mm² | Increased MACE risk [58]D |
| Lipid Arc | >180° | Marker of vulnerability [58]D |
| Macrophages | Presence on OCT | Indicator of active inflammation [58]D |
Differential Diagnosis
- ▸Aortic dissection can present with ischemic ECG changes and suspected MI; consider AAS before antithrombotic or invasive coronary treatment when the clinical context is concerning. [203][75]
- ▸In AF or atrial flutter, elevated high-sensitivity troponin is common and is often unrelated to MI; serial change and clinical context are essential. [68][204]
- ▸Chronic myocardial injury has been assessed using elevated troponin with sequential variation of **≤20%**, but short-interval sampling may limit reliability. [204]
- ▸Takotsubo syndrome, pheochromocytoma, PE/PTTM, hyperkalemia, urinary retention, and MINOCA can all mimic AMI or STEMI. [71][206][208][283][65][284][209]
- ▸Novel troponin forms, troponin complexes, exosomal microRNAs, gene-expression markers, and machine-learning models remain investigational adjuncts. [68][70][69][72][211][212]
Acute myocardial infarction (AMI) should be differentiated from other causes of chest pain, ischemic electrocardiographic (ECG) changes, myocardial injury, and acute ventricular dysfunction. A normal or abnormal troponin result does not, by itself, establish infarction: contemporary high-sensitivity assays detect myocardial injury from multiple cardiac and systemic conditions, and diagnosis requires integration of symptoms, serial biomarker change, ECG findings, imaging, and—when appropriate—coronary and aortic imaging. [68]D[204]
Acute aortic syndrome and aortic dissection
Acute aortic syndrome (AAS), particularly Stanford type A dissection, is a critical AMI mimic because it may present with chest or back pain, ischemic ECG changes, troponin elevation, and an initial clinical impression of myocardial infarction. In a large Swedish emergency-department study, missed AAS was specifically associated with ischemic ECG changes and an initial suspicion of MI, demonstrating that an apparently coronary presentation does not exclude dissection. [203] Undertriage of aortic dissection was also associated with delays in care in a multicenter emergency-department cohort, emphasizing the need for early recognition of this time-critical alternative. [75]D
The differential is especially important before antithrombotic treatment or invasive coronary intervention when dissection is clinically plausible. Stanford type A dissection has been investigated using peripheral-leukocyte messenger-RNA signatures, including a case-control comparison with AMI; these biomarkers remain investigational and should not replace definitive imaging. [69]D Machine-learning models using clinical and laboratory variables have likewise been developed to distinguish aortic dissection from non-ST-elevation MI, but the reported evidence is model-development evidence and requires external validation before routine use. [212]D
Pulmonary embolism and pulmonary vascular emergencies
Pulmonary embolism (PE) can produce chest discomfort, dyspnea, right-heart strain, ECG abnormalities, and elevated troponin, thereby resembling NSTEMI or occasionally STEMI. Pulmonary tumor thrombotic microangiopathy (PTTM) is a particularly rare, rapidly progressive alternative characterized by pulmonary hypertension and acute right-heart failure, often in patients with previously unknown adenocarcinoma. It may be diagnosed only post-mortem and can present as unexplained sudden cardiac death or refractory right-sided cardiogenic shock. [71]D Rapid recognition of unexplained pulmonary hypertension, severe right-heart failure, or an occult malignancy is therefore essential when the coronary explanation is incomplete. [71]D
Atrial fibrillation and non-infarction troponin elevation
Atrial fibrillation or atrial flutter commonly produces elevated troponin in emergency-department patients, although such elevations are infrequently caused by MI. The conventional high-sensitivity cardiac troponin T assay detects both intact and highly fragmented forms of troponin T and therefore identifies myocardial injury without reliably distinguishing MI from other causes of elevation. [68]D In the SuperTROPO study, 521 patients with AF alone and 188 with MI alone—all with admission total cTnT of ≥14 ng/L—were evaluated using intact and long-form cTnT measurements, supporting investigation of troponin composition as a potential discriminator. [68]D
Persistently elevated troponin may instead represent chronic myocardial injury. In a prospective accelerated-diagnostic-pathway analysis, chronic injury was defined as an elevated cTn concentration with sequential variation of ≤20%; however, the reliability of this criterion over short sampling intervals was specifically examined because small changes may not cleanly separate chronic injury from acute disease. [204] Novel assays measuring troponin complexes or long troponin forms, including cardiac troponin I–troponin T–troponin C complexes, have been evaluated as potential tools for differentiating MI from other myocardial-injury states, but these approaches remain supplementary rather than established replacements for clinical adjudication. [70]D
Takotsubo syndrome and catecholamine-mediated injury
Takotsubo syndrome (TTS) may closely mimic anterior STEMI, including overlapping symptoms, ECG abnormalities, biomarker elevation, and apical wall-motion abnormalities. Echocardiographic inferior-apex and inferolateral-apex ratios (IAR and ILAR), together with segmental strain, have been studied to distinguish typical TTS from anterior STEMI; these indices are promising diagnostic adjuncts but were evaluated retrospectively in 50 TTS and 50 AMI patients. [206] TTS may also cause severe cardiogenic shock requiring mechanical circulatory support, including extracorporeal membrane oxygenation, although outcome evidence is observational. [208]
Pheochromocytoma is an uncommon catecholamine-mediated AMI mimic. It can present with STEMI-pattern ECG changes, elevated cardiac enzymes, severe heart failure, marked blood-pressure variability, and angiographically normal coronary arteries. A large adrenal mass and elevated catecholamine levels support the diagnosis, particularly in a young patient or when coronary angiography shows no obstructive lesion. [283]C
MINOCA and other non-obstructive coronary presentations
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is not synonymous with a non-cardiac diagnosis; it is a heterogeneous clinical entity requiring diagnostic confirmation and further etiologic evaluation. Non-invasive algorithms using demographic, laboratory, imaging, and cardiac-marker variables have been developed to identify MINOCA, but available evidence is retrospective and should be interpreted as exploratory. [209]
Metabolic, abdominal, and ECG mimics
Hyperkalemia can cause dramatic ST-segment elevation and apparent STEMI while producing neither ACS nor stroke; weakness, paralysis, and the electrolyte abnormality may provide important clues. [65]C Massive urinary-bladder distension can also produce inferior pseudo-STEMI, including ST elevation in leads II, III, and aVF with reciprocal depression in leads I and aVL; resolution after catheterization supports a non-coronary mechanism. [284]C These examples reinforce that an ECG pattern alone should not be treated as definitive proof of coronary occlusion when clinical and laboratory findings are discordant.
ECG interpretation remains a major source of diagnostic error because STEMI equivalents, mimics, and evolving MI patterns can be difficult to distinguish. A 2026 study of emergency medical officers specifically evaluated knowledge of these patterns, underscoring the need for systematic ECG interpretation and rapid expert review when findings are uncertain. [253] Sex-related differences in symptom presentation, pathophysiology, and risk factors may further contribute to underdiagnosis of cardiac chest pain in women; sex-specific considerations should therefore be incorporated into the differential rather than relying on stereotypical symptoms. [213]D
Emerging biomarkers
Exosomal microRNA profiles and machine-learning models have been investigated for early AMI recognition and forensic or clinical differentiation. Plasma exosomal studies identified time-related changes in multiple microRNAs and constructed exploratory recognition models, but these biomarkers are not yet substitutes for validated clinical pathways. [72]D Similarly, CDK7 and other DNA-damage-response genes have been examined as exploratory markers for distinguishing STEMI from NSTEMI in a Bangladeshi cohort; these findings require independent validation before clinical adoption. [211]
| Differential diagnosis | Findings that may suggest the alternative | Evidence and limitation |
|---|---|---|
| Acute aortic syndrome/dissection | Chest or back pain, ischemic ECG changes, suspected MI, possible troponin elevation | Missed diagnosis is associated with ischemic ECG changes; urgent imaging is required when suspected. [203][75]D |
| AF/atrial flutter with myocardial injury | Tachyarrhythmia and elevated cTn without convincing infarction | Troponin elevation is frequent but seldom due to MI; serial change and clinical adjudication are required. [68]D[204] |
| PE/PTTM | Dyspnea, pulmonary hypertension, acute right-heart failure, unexplained shock or occult adenocarcinoma | PTTM is rare, rapidly fatal, and frequently diagnosed late or post-mortem. [71]D |
| Takotsubo syndrome | Stress-associated ventricular dysfunction, apical involvement, STEMI-like presentation | Echocardiographic IAR/ILAR and strain may help, but evidence is retrospective. [206] |
| Pheochromocytoma | STEMI pattern with normal coronaries, labile blood pressure, heart failure, adrenal mass | Catecholamine testing and imaging are diagnostic clues; evidence is case-report level. [283]C |
| Metabolic/abdominal pseudo-STEMI | Hyperkalemia with weakness or paralysis; massive bladder distension with inferior ST elevation | Resolution of the underlying abnormality may clarify the diagnosis. [65]C[284]C |
Supportive Care and Complication Management
- ▸SCAI classification is the gold standard for staging cardiogenic shock severity and guiding multidisciplinary Heart Team activation.
- ▸Mineralocorticoid receptor antagonists (MRAs) should be initiated within 60 days post-AMI for patients with LVEF <50%.
- ▸Microaxial flow pumps (mAFP) improve survival in STEMI-CS but increase BARC 3-5 bleeding risk to 26.3%.
- ▸Low free triiodothyronine (FT3) and high glycemic variability are significant predictors of post-infarction arrhythmias.
- ▸The CS4P risk score provides superior prognostic accuracy for cardiogenic shock compared to traditional models.
- ▸Varenicline is being investigated as a novel therapy for frequent PVCs (≥1,000/24 h) post-MI.
- ▸Concomitant IABP may be used with V-A ECMO to prevent left ventricular distension and promote myocardial recovery.
Management of Cardiogenic Shock (CS)
Cardiogenic shock (CS) remains a critical complication of acute myocardial infarction (AMI), characterized by high mortality and significant management variability [216]. Current consensus emphasizes standardized staging using the SCAI classification to guide therapy [216]. Key components of management include early recognition, continuous lactate monitoring, and the central role of echocardiography for hemodynamic assessment [216]. The CS4P biomarker-based risk score, which utilizes four specific proteins, has demonstrated advanced predictive metrics for mortality in both STEMI and NSTEMI patients, outperforming contemporary risk scores [93].
In patients with STEMI-related CS (STEMI-CS), cardiac arrest is a frequent concomitant event, occurring as out-of-hospital cardiac arrest (OHCA) in 34.8% of cases and in-hospital cardiac arrest (IHCA) in 21.7% [218]. Furthermore, spontaneous coronary artery dissection (SCAD) can lead to CS; these patients are statistically less likely to be female (OR 0.64) or have a history of prior MI (OR 0.71) compared to non-CS SCAD patients, yet they face significantly higher mortality [201].
Mechanical Circulatory Support (MCS)
The use of mechanical circulatory support in AMI-CS is evolving, though randomized controlled trials (RCTs) have shown inconsistent results due to heterogeneity in patient selection and intervention timing [217]. The DanGer Shock trial demonstrated that microaxial flow pumps (mAFP), such as the Impella, improve outcomes in STEMI-CS but are associated with a significant increase in major bleeding [94]. Specifically, BARC type 3-5 bleeding occurred in 26.3% of mAFP patients compared to 15.3% in those receiving standard care [94]. Despite these risks, mAFP support provides comparable benefits in both ischemic (AMI-CS) and non-ischemic cardiogenic shock [12]D.
For patients requiring veno-arterial extracorporeal membrane oxygenation (V-A ECMO) during percutaneous coronary intervention (PCI), the addition of an intra-aortic balloon pump (IABP) may be considered to mitigate ECMO-related left ventricular (LV) overload [225]. While the initial choice between IABP and mAFP remains debated in real-world settings, early hemodynamic-guided intervention is increasingly recommended [217][224]C. In cases of Killip class IV AMI complicated by pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF), mAFP use has been investigated for its impact on 30-day mortality [219].
Heart Failure and Ventricular Remodeling
Heart failure (HF) is the primary cause of death following AMI recovery [115]D. Early initiation of mineralocorticoid receptor antagonists (MRAs)—defined as initiation during index hospitalization or within 60 days—is safe and effective for patients with post-AMI cardiac dysfunction, specifically those with a left ventricular ejection fraction (LVEF) <50% [99].
At the molecular level, adverse cardiac remodeling and fibrosis are promoted by the E3 ubiquitin ligase TRIM21, which mediates the K48-linked ubiquitination of the ALDH2 rs671 mutant [115]D. Clinically, insulin resistance, as measured by the triglyceride-glucose (TyG) index, is a potent predictor of in-hospital acute heart failure (AHF) following emergency PCI [111]D.
Arrhythmia and Electrophysiological Monitoring
Arrhythmias are common post-AMI and require nuanced management. New-onset atrial fibrillation (AF) is categorized by timing: early (during index hospitalization) or late (after discharge), both of which carry distinct prognostic implications [223]. High glycemic variability (GV) during hospitalization is significantly associated with an increased risk of AF and in-hospital mortality [222].
For ventricular arrhythmias (VA), plasma free triiodothyronine (FT3) levels serve as a novel biomarker; lower FT3 levels are independently associated with a higher risk of VA during hospitalization [101]. In patients with frequent premature ventricular complexes (PVCs) (≥1,000/24 h) at ≥4 weeks post-MI, the partial nicotinic acetylcholine receptor (nAChR) agonist varenicline has been explored as a novel non-ion channel-targeting antiarrhythmic [214].
Continuous monitoring via implantable cardiac monitors (ICM) was studied in the BIO|GUARD-MI trial, but the study was terminated prematurely due to performance bias in the unblinded treatment group, which reported a higher incidence of non-cardiovascular adverse events [215].
Renal and Metabolic Complications
Acute kidney injury (AKI) is a major predictor of mortality in AMI-related CS [221]. A LASSO regression-based nomogram has been developed to predict the need for in-hospital renal replacement therapy (RRT), facilitating earlier intervention [221]. Additionally, the use of intravenous antiplatelet therapies, such as cangrelor or glycoprotein IIb/IIIa inhibitors, in the context of CS requires a careful balance between preventing major adverse cardiovascular events (MACE) and minimizing the risk of major bleeding [220].
| Intervention | Population | Key Outcome | Statistical Threshold |
|---|---|---|---|
| mAFP (Impella) | STEMI-CS | BARC 3-5 Bleeding | 26.3% vs 15.3% (Standard Care) |
| MRA Initiation | AMI + LVEF <50% | Safety/Efficacy | Initiation within 60 days |
| Varenicline | Post-MI | PVC Reduction | Baseline PVCs ≥1,000/24 h |
| SCAI Staging | AMI-CS | Mortality Risk | Standardized Staging (A-E) |
Prognosis and Long-term Outcomes
- ▸Prognosis after AMI is heterogeneous and is shaped by myocardial injury, reperfusion quality, ventricular function, comorbidity, recurrent events, and secondary prevention. [254][233][256]
- ▸Recurrent MI, including troponin-detected events, is associated with clinically important short- and intermediate-term risk and may warrant systematic biochemical and imaging assessment. [287][294]
- ▸Bivalirudin reduced 30-day death and major bleeding versus heparin in BRIGHT-4, including analyses by baseline bleeding risk. [285]
- ▸Long-term risk assessment should account for diabetes, COPD, obesity, inflammation, acute heart-failure phenotype, cardiogenic shock, and cardiac MRI or CT-derived markers. [179][233][256][257][258][261][263][291][293][294]
- ▸Intracoronary mesenchymal stem-cell therapy remains investigational because randomized evidence is limited and inconsistent. [254]
Overview
Despite contemporary reperfusion and secondary-prevention strategies, acute myocardial infarction (AMI)—particularly ST-segment elevation myocardial infarction (STEMI)—can result in irreversible myocardial injury, adverse ventricular remodeling, recurrent infarction, heart failure, and death. [254] Prognosis is heterogeneous and depends on ischemic burden, reperfusion quality, ventricular function, comorbidities, complications, and the effectiveness of long-term preventive treatment. [233][256]
Recurrent infarction and mortality
Recurrent MI is a clinically important prognostic event. In the MINT trial, suspected recurrent infarctions were identified both by site reporting and by centralized review of troponin measurements obtained during the first 3 days after randomization; outcomes were compared at 30 and 180 days according to whether patients had a site-reported MI, only a centrally identified MI, or no recurrent MI. [287] The study specifically addressed whether routine troponin surveillance improves recognition of recurrent infarction and its prognostic classification, highlighting that biochemical events may be missed by conventional clinical ascertainment. [287]
Among patients experiencing a second MI, ischemic mitral regurgitation (IMR) may evolve dynamically. In a retrospective cohort of 4,091 patients treated with primary PCI for AMI, 88 experienced recurrent MI and underwent echocardiography before recurrence, at recurrence, and at discharge; persistent or worsening IMR was evaluated in relation to 5-year adverse outcomes, including all-cause death and heart-failure-related events. [294] These findings support serial echocardiographic assessment when recurrent infarction is complicated by new or changing mitral regurgitation. [294]
Reperfusion, revascularization, and long-term risk
Procedural strategy can influence early outcomes that may affect longer-term prognosis. In the BRIGHT-4 STEMI trial, 6,016 patients undergoing radial-access primary PCI were randomized to bivalirudin with a 2–4-hour post-PCI high-dose infusion or heparin monotherapy; bivalirudin reduced the 30-day composite of all-cause death or BARC type 3–5 bleeding, as well as death and bleeding individually. [285] A prespecified analysis examined whether these benefits applied to both low-bleeding-risk and non-low-bleeding-risk patients. [285]
The RAPID-POP randomized trial evaluated whether maintaining stent inflation until pressure stability—defined as no pressure fall of ≥0.3 atm over 30 seconds, after inflation to ≥14 atm—improved hierarchical reperfusion success compared with conventional rapid inflation-deflation stenting during primary PCI. [286] The rationale was that incomplete microvascular reperfusion remains a major limitation of STEMI treatment and may contribute to subsequent myocardial dysfunction. [286]
For STEMI with multivessel disease, the 10-year DANAMI-3-PRIMULTI substudy assessed patients whose nonculprit lesions were managed using FFR-guided decision-making. [288] Among 627 trial participants, 280 were included in the substudy; patients with nonculprit FFR >0.80 and deferred PCI were compared with patients who underwent PCI of at least one nonculprit lesion. [288] This study provides long-term comparative evidence relevant to whether physiologically non-significant nonculprit disease requires intervention. [288]
Secondary prevention and disease modification
SGLT2 inhibitors are being evaluated after AMI in patients with and without diabetes. A 2026 systematic review and meta-analysis included 31,378 patients, of whom 10,897 (34.7%) received an SGLT2 inhibitor; the evidence base combined randomized and observational studies and specifically examined whether benefits were restricted to diabetes. [289] Because the pooled evidence incorporated heterogeneous study designs, treatment effects should be interpreted according to the underlying evidence quality and patient phenotype. [289]
After coronary revascularization, ticagrelor monotherapy and aspirin monotherapy were compared in a systematic review of randomized trials involving PCI or CABG. [290] The primary outcome was MACE, defined as all-cause mortality, MI, or stroke; secondary outcomes included mortality, MI, stroke, major bleeding, repeat revascularization, and stent thrombosis. [290] These outcomes represent the principal competing ischemic and bleeding risks relevant to long-term antiplatelet selection. [290]
In people with dementia, a large retrospective cohort spanning Australia, Finland, Taiwan, the United Kingdom, and the United States evaluated post-MI use of statins, renin–angiotensin-system inhibitors, and beta-blockers, including combinations of these guideline-recommended drug classes. [262] The study addressed cardiovascular outcomes and mortality in a population often underrepresented in trials, but its observational design limits causal interpretation. [262]
Prognostic modifiers and risk stratification
Diabetes identifies a higher-risk STEMI subgroup, but risk is not uniform. A systematic review and meta-analysis evaluated standard modifiable and non-standard modifiable risk factors associated with mortality after STEMI in people with diabetes, with evidence searched through 3 May 2025. [256] A separate dual-cohort study developed and externally validated an admission-based model for 180-day mortality in diabetic AMI using routine variables and compared its prognostic information with GRACE-based assessment. [233]
Other comorbidities also modify prognosis. In a prospective registry cohort of STEMI patients treated with PCI, obesity—defined as BMI ≥30 kg/m²—was assessed against non-obesity for 1-year MACE, including death and recurrent ACS. [257] In patients with COPD and prior AMI, a retrospective cohort using spirometric airflow-obstruction severity examined 5-year all-cause mortality. [293] In critically ill NSTEMI, a multinational cohort of 7,815 patients evaluated BMI, systemic inflammation measured by CRP, and both in-hospital and 10-year mortality, with external validation in two United States databases. [179]C
Faster reperfusion may not benefit all patients equally. A retrospective cohort of 4,513 STEMI patients undergoing primary PCI examined whether door-to-balloon time ≤60 minutes was associated with short- and long-term outcomes according to GRACE risk category. [292] Cardiac MRI-derived biventricular mechanics may provide additional prognostic information: a multicenter retrospective study evaluated the LV-to-RV global longitudinal strain ratio in isolated LV infarction and its association with all-cause mortality. [261]
Inflammation and systemic phenotype are additional areas of risk assessment. Population and imaging cohorts examined circulating IL-18, an inflammasome-dependent cytokine, in relation to coronary events and atherosclerosis severity among more than 60,000 participants across three studies. [258] In the SCOT-HEART trial, machine-learning analysis of coronary CT angiography body composition assessed associations between multiorgan tissue characteristics and 10-year MI and all-cause mortality in 1,722 patients. [234]
High-risk complications and emerging therapies
Acute heart failure phenotypes—including acute decompensated heart failure, acute pulmonary edema, isolated right-ventricular failure, and cardiogenic shock—have distinct clinical characteristics and were compared for 1-year all-cause and cardiovascular mortality in a real-world emergency-department study. [291] Among cardiogenic-shock patients requiring venoarterial ECMO, a nationwide Japanese study compared Impella with intra-aortic balloon pump unloading using propensity-weighted analysis; the retrospective design limits definitive treatment comparisons. [263]C
Intracoronary MSC therapy remains investigational. A meta-analysis of eight randomized trials involving 796 STEMI patients, with seven trials and 400 patients included quantitatively, evaluated efficacy and safety versus standard care in the setting of persistent myocardial injury and adverse remodeling despite reperfusion. [254] The inconsistency of existing trial evidence means that MSC administration should not be considered established routine prognostic therapy. [254]
| Domain | Evidence and relevant time horizon |
|---|---|
| Recurrent infarction | Centralized troponin review in MINT evaluated recurrent MI and outcomes at 30 and 180 days. [287] |
| Recurrent MI with IMR | Serial echocardiography assessed dynamic IMR and 5-year adverse outcomes. [294] |
| Revascularization strategy | FFR-guided nonculprit-lesion management was evaluated over 10 years in DANAMI-3-PRIMULTI. [288] |
| Comorbidity | Diabetes, obesity, COPD, and critical illness were associated with distinct risk profiles across 1-year, 5-year, and 10-year outcomes. [179]C[233][256][257][293] |
| Advanced imaging | Cardiac MRI strain and CT-derived body composition were evaluated as mortality or MI predictors. [234][261] |
Special Populations
- ▸Sex-stratified evidence after PCI includes 1,002 women and 4,504 men randomized to clopidogrel or aspirin monotherapy after standard dual antiplatelet therapy. [296]
- ▸Post-MI risk assessment should include diabetes, the full glycaemic spectrum, metabolic-inflammatory burden, and the possibility of heart failure after emergency PCI. [273,305,308]
- ▸The BRIGHT-4 bleeding-risk analysis evaluated bivalirudin versus heparin in both low- and non-low-bleeding-risk STEMI patients; low bleeding risk was defined with the CRUSADE score. [285]
- ▸Prior CABG, cardiogenic shock after resuscitated cardiac arrest, and NSTE-ACS requiring invasive assessment are distinct populations requiring tailored diagnostic and therapeutic interpretation. [302,304,306]
- ▸Adherence, diet, reperfusion timing, microvascular injury, and residual non-target-vessel risk are clinically relevant post-MI domains supported by recent cohort, randomized, and meta-analytic evidence. [289,292,295,297,298,299,301]
Women and men after PCI
Sex-specific evidence is available from a prespecified analysis of SMART-CHOICE 3, which randomized high-risk patients who had completed standard dual antiplatelet therapy after PCI to clopidogrel or aspirin monotherapy. The analysis included 1,002 women and 4,504 men and evaluated a composite of all-cause death, myocardial infarction, or stroke, allowing assessment of whether the relative treatment effect differed by sex. [296] Sex should therefore be considered when interpreting maintenance antiplatelet evidence, although treatment decisions remain dependent on ischemic and bleeding risk and the patient’s clinical context. [296]
Diabetes, dysglycaemia, and metabolic risk
The post-MI risk spectrum includes patients with diabetes, prediabetic-range abnormalities, and apparently normal glycaemia. A Swedish registry study included 47,558 adults attending cardiac rehabilitation after MI, with available diabetes, fasting-glucose, and HbA1c data, and assessed major adverse cardiovascular events comprising all-cause mortality, MI, and ischemic stroke. [305] In patients with type 2 diabetes and STEMI undergoing emergency PCI, a retrospective study of 306 adults examined factors associated with new-onset in-hospital heart failure and developed an internally validated prediction model; 65 patients were classified in the heart-failure group and 241 in the non-heart-failure group. [308]
Metabolic and inflammatory burden may also be relevant after reperfusion. In a single-centre retrospective cohort of 318 STEMI patients who achieved post-PCI TIMI grade 3 flow, the triglyceride-glucose index and inflammatory burden index were evaluated in relation to angiographic microvascular resistance-defined coronary microvascular dysfunction and 12-month major adverse cardiovascular events. [273] These findings support risk assessment beyond diabetes status alone, but the observational designs do not establish that modifying either index improves outcomes. [273][305][308]
SGLT2 inhibitors are being evaluated across diabetic and nondiabetic post-MI populations. A 2026 systematic review and meta-analysis included 31,378 patients, of whom 10,897 received an SGLT2 inhibitor, and compared SGLT2 inhibitors with standard care after acute MI; the review specifically examined whether benefit was limited to patients with diabetes. [289] The DAPA-MI randomized trial also provides the setting for objective assessment of adherence to dapagliflozin or placebo using digital bottle-cap data in patients after MI. [295]
Patients at increased bleeding risk
In STEMI patients undergoing radial primary PCI, the BRIGHT-4 trial compared bivalirudin plus a 2–4-hour post-PCI high-dose infusion with heparin monotherapy. A prespecified analysis examined whether the reported reduction in the 30-day composite of all-cause death or BARC type 3–5 bleeding, as well as death and bleeding individually, applied both to patients at low bleeding risk and to those who were not at low bleeding risk; low bleeding risk was defined using the CRUSADE score. [285] Antithrombotic selection should therefore account explicitly for baseline bleeding risk rather than assuming that trial effects are confined to a low-risk subgroup. [285]
Patients with prior CABG and diagnostic uncertainty
Patients with previous coronary artery bypass grafting represent a high-risk diagnostic subgroup. A prospective international multicentre diagnostic study directly compared the ESC 0/1-hour and 0/2-hour high-sensitivity cardiac troponin T/I algorithms in patients with prior CABG presenting with acute chest discomfort. The study used centrally adjudicated diagnoses according to the Universal Definition of MI and assessed safety and efficacy, including the proportion triaged to rule-in or rule-out. [302]
Cardiogenic shock and cardiac arrest
Cardiogenic shock after resuscitated out-of-hospital cardiac arrest differs mechanistically from non-arrest cardiogenic shock because end-organ hypoperfusion may arise through distinct pathways. A retrospective international derivation cohort of 627 patients and external validation in 1,781 participants from TTM-2 evaluated the SCAI-V classification, using mortality and non-neurological mortality as outcomes. [304]C These patients require separate assessment of shock severity, neurological prognosis, and end-organ injury rather than direct application of evidence from uncomplicated MI. [304]C
Older or medically complex post-MI patients
In patients without recorded heart failure, an observational French National Health Data System cohort compared atenolol with bisoprolol when dispensed within 2 days of discharge after a new MI; eligible patients were adults hospitalized between 2008 and 2018 without prior heart-failure diagnosis, β-blocker use, or loop-diuretic use during the preceding 2 years. [303] The study informs comparative β-blocker prescribing but, because it was observational, does not prove equivalence or superiority of either agent. [303]
Adherence and lifestyle after MI
Objective adherence measurement is especially relevant in post-MI patients because nonadherence is a recognized obstacle to cardiovascular disease management. The DAPA-MI adherence substudy characterized daily adherence and dose consistency using digital bottle-cap data, investigated patient and contextual factors associated with nonadherence, and examined whether dose consistency was associated with adherence over time. [295] Among MI survivors in the Nurses’ Health Study and Health Professionals Follow-Up Study, 3,277 women and 2,618 men with nonfatal MI were followed using repeated food-frequency assessments; the study evaluated adherence to eight healthy dietary patterns and changes in adherence from before to after MI in relation to mortality. [301]
Procedural and residual-risk subgroups
For STEMI with multivessel disease after successful culprit-lesion treatment, an international randomized trial compared complete revascularization guided by functional coronary angiography with angiography-guided complete revascularization; the composite outcome included death, MI, stroke or transient ischemic attack, and ischemia-driven revascularization. [298] In patients undergoing primary PCI for STEMI, the RAPID-POP randomized trial compared pressure-optimized stenting— inflation to ≥14 atm until pressure stability, defined as no pressure fall of ≥0.3 atm over 30 seconds—with rapid inflation-deflation stenting to address incomplete microvascular reperfusion. [286] Other studies evaluated angiography-based microcirculatory resistance in 123 STEMI patients randomized to pre-PCI recombinant staphylokinase or saline, [299] and examined the triglyceride-glucose and inflammatory indices as predictors of microvascular dysfunction. [273] Artificial-intelligence-derived radial wall strain from routine angiography was assessed in a post hoc TARGET All Comers analysis as a potential predictor of five-year events in untreated non-target vessels. [297]
NSTE-ACS and platelet-response subgroups
In NSTE-ACS patients managed with a planned invasive strategy, a UK observational policy comparison evaluated routine P2Y12-inhibitor pretreatment versus no routine pretreatment before coronary anatomy was known. [306] After STEMI, a randomized pilot study compared continued ticagrelor with serial platelet-function-guided P2Y12 modulation after a 1-month ticagrelor run-in; the guided group used clopidogrel 75 mg or 150 mg according to ADP results, with platelet reactivity assessed through 12 months. [300]C
Other diagnostic populations
A machine-learning radiomics study evaluated noncontrast postmortem CT for autopsy-confirmed MI in 106 examinations, including 55 MI cases and 51 controls. [307] This evidence is relevant to forensic diagnosis rather than acute-care treatment. [307]
Timing of reperfusion
A retrospective cohort of 4,513 STEMI patients treated with primary PCI examined whether door-to-balloon time of ≤60 minutes was associated with short- and long-term outcomes across GRACE-risk strata. [292] Because the study was single-centre and observational, the prognostic meaning of this threshold may vary according to baseline risk and cannot by itself establish a universal treatment target for every patient. [292]
| Population or issue | Updated evidence | Practical implication |
|---|---|---|
| Sex after PCI | SMART-CHOICE 3 sex-stratified analysis: 1,002 women and 4,504 men; clopidogrel versus aspirin monotherapy. [296] | Consider sex when interpreting antiplatelet evidence. [296] |
| Diabetes and dysglycaemia | Swedish registry: 47,558 post-MI rehabilitation patients; outcomes across diabetes, fasting glucose, and HbA1c. [305] | Do not restrict risk assessment to diagnosed diabetes. [305] |
| Bleeding risk | BRIGHT-4 prespecified analysis: bivalirudin versus heparin in low- and non-low-risk patients. [285] | Incorporate baseline bleeding risk into anticoagulant selection. [285] |
| Prior CABG | Direct comparison of ESC 0/1-hour and 0/2-hour hs-cTn algorithms. [302] | Use validated diagnostic pathways while recognizing the high-risk subgroup. [302] |
| Cardiac arrest with shock | SCAI-V derivation and external validation in 627 and 1,781 patients. [304]C | Assess arrest-related shock separately from conventional cardiogenic shock. [304]C |
| Adherence and lifestyle | Digital bottle-cap adherence assessment after MI and prospective dietary-pattern analysis in 5,895 MI survivors. [295][301] | Address medication-taking behavior and dietary recovery as part of secondary prevention. [295][301] |
Guidelines and Resources
- ▸Use the **2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS guideline** as the newest listed overarching guideline; it supersedes earlier STEMI, NSTEMI, primary-PCI, and relevant revascularization guidance. [153]
- ▸Primary PCI is the standard reperfusion strategy in most Japanese institutions and has reduced STEMI mortality, including in cardiogenic shock. [154]
- ▸Consider intravascular imaging to guide PCI in accordance with the 2023 ESC-related update. [154]
- ▸Integrate high-sensitivity troponin algorithms with symptoms and ECG; the 0/1-hour pathway should not be used indiscriminately in early presenters. [157]
- ▸Individualize DAPT duration according to ischemic and bleeding risk and reassess it over time; reported durations range from **1–36 months** in selected patients. [168]
- ▸Use the SCAI cardiogenic-shock stages to communicate shock severity in AMI. [156]
Current overarching guidance
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline is the most recent listed North American guideline for acute coronary syndromes (ACS). It incorporates evidence published after the 2013 ACCF/AHA STEMI guideline, the 2014 AHA/ACC non-ST-elevation ACS guideline, and the 2015 ACC/AHA/SCAI focused update on primary PCI for STEMI. It also retires and replaces these earlier ACS documents and supersedes the 2021 ACC/AHA/SCAI coronary revascularization guideline where applicable. [153] The listed evidence designation for this guideline is 5, whereas the other resources in this section are designated 1c. [153-169]
The 2024 CVIT expert consensus document updates the Japanese recommendations for procedural management of primary PCI in ACS, following earlier CVIT documents published in 2018 and 2022. [154] Primary PCI has substantially reduced mortality in STEMI, including among patients with cardiogenic shock, and is described as the standard of care in most Japanese institutions. [154] The document incorporates major changes from the 2023 ESC ACS guideline, including consideration of intravascular imaging to guide PCI (Class IIa as reported in the source abstract). [154]
Initial assessment and emergency pathways
Prehospital assessment should address chest pain or acute dyspnoea of suspected cardiac origin, with practical guidance for emergency medical service personnel on initial diagnostic work-up, treatment during transport, and transfer to an appropriate facility. [158] Earlier ACC/AHA emergency-department guidance emphasized rapid recognition and prompt initiation of reperfusion for STEMI. [161][163] Aspirin was recommended for symptomatic patients, while acute beta-blocker treatment was advised cautiously because of potential associations with cardiogenic shock and death. [163]
For suspected ACS without persistent ST-segment elevation, high-sensitivity cardiac troponin testing and serial interpretation should be integrated with the clinical context and ECG findings. [157] The 2015 ESC diagnostic strategy discussed 0/1-hour and 0/3-hour rule-in/rule-out approaches; the source specifically reports that approximately 75% of emergency patients could be discharged early using the 0/1-hour algorithm, while warning that it should not be applied to early presenters soon after chest-pain onset without appropriate validation. [157] The 2015 ESC update also addressed invasive-strategy timing, catheter-based treatment, periprocedural antithrombotic therapy, and secondary prevention. [169]
Reperfusion and PCI resources
The 2009 ACC/AHA focused updates revised earlier STEMI and PCI guidance in response to accumulating clinical-trial evidence and were intended to support contemporary interventional practice. [160] The 2007 focused update likewise addressed emergency-department treatment decisions and implementation of timely, multidisciplinary, evidence-based care. [161] The 2009 guideline update identified early reperfusion as the cornerstone of STEMI management and supported aspirin and clopidogrel-based treatment, while emphasizing caution with beta blockers in the acute setting. [163]
The 2024 CVIT consensus is the most recent listed resource specifically focused on procedural primary PCI in ACS. [154] It should be used alongside contemporary ACS guidance when considering lesion assessment, PCI technique, and intravascular imaging. [154] The 2023 ESC-related update highlighted intravascular imaging as a technology that should be considered to guide PCI. [154]
Cardiogenic shock and mechanical support
Cardiogenic shock complicating myocardial infarction remains associated with poor outcomes despite the availability of percutaneous mechanical circulatory-support devices. [156] The SCAI expert consensus therefore proposed a multidisciplinary classification system to describe different stages of cardiogenic shock, with participation from interventional and advanced-heart-failure cardiology, emergency medicine, critical care, and cardiac nursing. [156] The classification was endorsed by the ACC, AHA, Society of Critical Care Medicine, and Society of Thoracic Surgeons in April 2019. [156] Primary PCI remains relevant in STEMI with shock, but shock severity should be communicated using a standardized clinical framework. [154][156]
Antiplatelet therapy and secondary prevention
Dual antiplatelet therapy (DAPT), consisting of low-dose aspirin plus a P2Y12 inhibitor, is a central treatment strategy after PCI and in ACS, including STEMI, NSTEMI, and unstable angina. [165][168] The 2017 ESC-focused update discussed selection among clopidogrel, prasugrel, and ticagrelor and recognized that modern drug-eluting stents reduced the need for prolonged DAPT in elective PCI. [165] DAPT duration should be individualized according to ischemic and bleeding risk, may be considered for approximately 1–36 months in selected patients, and should be reassessed dynamically rather than determined solely by stent type. [168] The 2009 STEMI update specifically supported clopidogrel combined with aspirin after STEMI. [163]
Additional diagnostic and operational resources
The ACP/ACCF/AHA and collaborating-society guideline addresses diagnosis of known or suspected stable ischemic heart disease and was developed from literature searches covering multiple databases through November 2011. [159] Although it is not an acute-infarction guideline, it may assist with evaluation when the presentation is not clearly acute. [159] EANM/ESC guidance covers radionuclide assessment of right- and left-ventricular ejection fraction, ventricular volumes, regional and diastolic function, and the use of first-pass and equilibrium radionuclide ventriculography, gated myocardial-perfusion scintigraphy, gated PET, and non-imaging techniques. [162]
Operational quality data also matter: in the CRUSADE initiative, NSTEMI patients presenting outside regular hours had higher-risk profiles and were treated less aggressively, but their outcomes were not worse. [166] Older ACC/AHA guidance for unstable angina/NSTEMI was based on multicenter trials and emerging pharmacologic and catheter-based technologies, but it has been superseded by newer ACS recommendations. [167]
COVID-19-era resource
During the COVID-19 pandemic, SCAI, ACC, and ACEP issued a position statement recommending a systematic approach to AMI care while recognizing two simultaneous issues: most patients requiring ischemic-heart-disease care were not infected, whereas COVID-19 could produce complex cardiovascular presentations, including AMI and myocarditis mimicking AMI. [155] This document is principally a pandemic-era contingency resource and should be interpreted in the context of current ACS and infection-control policies. [155]
| Clinical domain | Most relevant listed resource | Main contribution |
|---|---|---|
| Overall ACS management | 2025 ACC/AHA/ACEP/NAEMSP/SCAI | Current overarching ACS guideline; replaces earlier major ACS documents. [153] |
| Primary PCI | 2024 CVIT consensus; 2023 ESC updates | Procedural primary-PCI guidance; intravascular imaging should be considered. [154] |
| STEMI emergency care | ACC/AHA focused updates | Reperfusion urgency, aspirin, cautious beta-blocker use, and antiplatelet therapy. [160][161][163] |
| NSTEMI diagnosis | ESC 2015 resources | High-sensitivity troponin algorithms and invasive-strategy timing. [157][169] |
| Cardiogenic shock | SCAI consensus | Multidisciplinary staged shock classification. [156] |
| DAPT | ESC 2017 updates | Individualize duration by ischemic and bleeding risk. [165][168] |
| Prehospital care | ESC/ACCA position paper | EMS assessment, treatment, and transfer pathways. [158] |
References
- [1]
Di Fusco SA, Matteucci A, Alonzo A et al.. “Beta-Blocker Therapy After Myocardial Infarction: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.” International journal of molecular sciences (2026). PMID: 41828582 ↗
L1aSR_MA_RCTCited in: Definition, Synonyms, and Classification - [2]
Yang Y, Liao M, Liu X et al.. “Prognostic Impact of Renin-Angiotensin System Inhibitors in Revascularized Patients with Acute Myocardial Infarction and Preserved or Mildly Reduced Ejection Fraction: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 41976977 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [3]
Smidtslund P, Harjutsalo V, Thorn V et al.. “Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study.” The lancet. Diabetes & endocrinology (2026). PMID: 41871591 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations - [4]
Kryeziu B, Poniku A, Henein MY et al.. “Epidemiological 11-Year Dynamics Study of Acute Myocardial Infarction: A Cohort Study in a Country with a Transitional Healthcare System.” Global heart (2026). PMID: 41766718 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [5]
Lu G, Wang X, Wang X et al.. “Case Report: Rapid progression of inflammation-driven coronary artery lesions in a normolipidemic patient with ANCA-associated vasculitis complicated by Stanford type A aortic dissection.” Frontiers in immunology (2026). PMID: 41909680 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [6]
Khalaf Y, Atta S, Helal A et al.. “Survival Beyond the Odds: Twelve-Week Follow-Up After Conservative Management of Post-Infarction Ventricular Free Wall Rupture.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41772389 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [7]
Vural A, Dolanbay T, Cumaoglu MO et al.. “Metabolic risk factors associated with premature myocardial infarction in adults ≤ 35 years: a case-control study.” BMC cardiovascular disorders (2026). PMID: 41776422 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [8]
Madandar E, Zarinfar Y, Namazi MH et al.. “Associations of Endothelial-Related lncRNAs with Early-Onset STEMI: A Case-Control Study.” Journal of cardiovascular translational research (2026). PMID: 41758284 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [9]
Chen S, Wang R, Ma J et al.. “Impact of a Prehospital Chest Pain Alert App-Mediated Prehospital-in-Hospital Coordination Model on Treatment Delays and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction: Protocol for a 4-Year Retrospective Real-World Cohort Study.” JMIR research protocols (2026). PMID: 41973638 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations - [10]
Zhang Y, Wang S, Fang Z et al.. “Predictive Performance of Serum Monomeric C-Reactive Protein for Major Adverse Cardiovascular Events in Patients With Acute ST-Segment Elevation Myocardial Infarction at One-Year Post-Discharge: A Retrospective Cohort Study.” British journal of hospital medicine (London, England : 2005) (2026). PMID: 41914002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations - [11]
Zhao J, Hong H, Fanaroff A et al.. “Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry.” American heart journal (2026). PMID: 41990900 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [12]
Ughetto A, Schrage B, Fürholz M et al.. “Beyond the STEMI Paradigm: Expanding the Scope of microAxial Flow Pump in Cardiogenic Shock.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2026). PMID: 41966345 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Speckauskiene V, Meilutyte-Lukauskiene D, Cerapaite-Trusinskiene R et al.. “Prognostic utility of Killip classification in acute myocardial infarction: a retrospective cohort analysis in contemporary clinical practice.” European heart journal open (2026). PMID: 41958748 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Aleksova A, Janjusevic M, Marketou M et al.. “Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI.” Progress in cardiovascular diseases (2026). PMID: 41956273 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [15]
Graves JM, Waken RJ, Wang F et al.. “Acute Myocardial Infarction in Medicare Beneficiaries During and After the COVID-19 Pandemic.” JAMA network open (2026). PMID: 41920542 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [16]
Kim CH, Joh HS, Kim HK et al.. “Comparison of Clinical Outcomes Between Incomplete and Complete Revascularization in NSTEMI Patients With Multivessel Disease.” JACC. Asia (2026). PMID: 41920117 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
Laffan J, Gao H, Street A et al.. “Outcomes according to timely or delayed primary percutaneous coronary intervention or fibrinolysis in a national registry of patients with ST-segment elevation myocardial infarction.” Open heart (2026). PMID: 41916670 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations - [18]
Lugo-Gavidia LM, Saucedo JF, Arias-Mendoza A et al.. “Implementing the GWTG-CAD Program in Mexico: Feasibility, Challenges and Lessons Learned for Acute and Secondary Prevention and Management.” Journal of the American Heart Association (2026). PMID: 41914361 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [19]
Zhao Y, Chen XY, Zhu GJ et al.. “Incremental prognostic value of left atrial strain for heart failure-related events following ST-Segment elevation myocardial infarction.” European journal of radiology (2026). PMID: 41894993 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [20]
Pozzessere P, Di Lauro M, Incantalupo F et al.. “Evaluating the Efficacy of CPS, HEART and TIMI Score in Emergency Department Patients with Non-Traumatic Chest Pain: A Pilot Study.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892866 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [21]
Beske RP, Klein A, Jensen LO et al.. “Early clinical recovery in STEMI cardiogenic shock: insights from the DanGer shock trial.” European heart journal. Acute cardiovascular care (2026). PMID: 41873805 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [22]
Palmisano T, Bilchick K, Guarraia D. “Hemoglobin A1c is more predictive of type 1 myocardial infarction than low-density lipoprotein or body mass index.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41864779 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [23]
Sharkey SW, Herman R, Witt DR et al.. “Performance of Artificial Intelligence-Powered ECG Analysis in Suspected ST-Segment Elevation Myocardial Infarction.” JACC. Advances (2026). PMID: 41863986 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [24]
Bilato C, Girardi G, Zuin M et al.. “Temporal trend in epidemiology and performance indicators of acute myocardial infarction: A 25 years population-based study.” International journal of cardiology (2026). PMID: 41861850 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [25]
Mavridis A, Viktorisson A, Leósdóttir M et al.. “Medication adherence after myocardial infarction: Predictors, mortality and cardiovascular outcomes.” Atherosclerosis (2026). PMID: 41856699 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [26]
Hu D, Wu D, Huang T et al.. “Monocyte-to-lymphocyte ratio as a predictor of left ventricular aneurysm in acute STEMI patients.” Frontiers in endocrinology (2025). PMID: 41847671 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Ahmadi-Beni M, Mokhtarian K, Mobini GR et al.. “Fasciola hepatica-Derived Proteins Shield the Heart From Type 2 Myocardial Infarction in Rats by Modulating Oxidative Stress and Inflammatory Imbalance: Insights Relevant to the Hygiene Hypothesis.” Oxidative medicine and cellular longevity (2026). PMID: 41823333 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Möser C, Prystupa K, Schön M et al.. “Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study.” Cardiovascular diabetology (2026). PMID: 41821026 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [29]
Kuku KO, Lenselink C, Venema CS et al.. “Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After ST-Segment-Elevation Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41804884 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [30]
Zhang YK, Shao X, Hu ST et al.. “Development and Validation of a Prognostic Model for One-year Mortality in Older Adults with Acute Myocardial Infarction Incorporating Activities of Daily Living Impairment.” Clinical interventions in aging (2026). PMID: 41799377 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [31]
Morosato M, Gaspardone C, Romagnolo D et al.. “Left Main Spontaneous Coronary Artery Dissection: Clinical Features, Management, and Outcomes.” JACC. Cardiovascular interventions (2025). PMID: 40208153 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [32]
O'Donoghue ML, Morrow DA, Vavere AL et al.. “Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial.” Nature medicine (2025). PMID: 40999229 ↗
L1bRCTCited in: Etiology and Triggering Factors - [33]
Gebert ZM, Kwiecinski J, Weir-McCall JR et al.. “Impact of diabetes mellitus on coronary artery plaque characteristics and outcomes in the SCOT-HEART trial.” Journal of cardiovascular computed tomography (2025). PMID: 39788814 ↗
L1bRCTCited in: Etiology and Triggering Factors - [34]
Kolossváry M, Lin A, Kwiecinski J et al.. “Coronary Plaque Radiomic Phenotypes Predict Fatal or Nonfatal Myocardial Infarction: Analysis of the SCOT-HEART Trial.” JACC. Cardiovascular imaging (2025). PMID: 39480364 ↗
L1bRCTCited in: Etiology and Triggering Factors - [35]
Nurmohamed NS, Min JK, Anthopolos R et al.. “Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.” European heart journal (2024). PMID: 39101625 ↗
L1bRCTCited in: Etiology and Triggering Factors - [36]
Rexhaj E, Bär S, Soria R et al.. “Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.” Atherosclerosis (2024). PMID: 38513436 ↗
L1bRCTCited in: Etiology and Triggering Factors - [37]
Hong XL, Loh YH, Li DB et al.. “Intracoronary administration of tenecteplase to prevent PCI-related myocardial infarction in patients with echo-attenuated coronary plaques: study protocol for a multicenter, prospective, randomized controlled trial.” Trials (2024). PMID: 39587685 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [38]
Zhao J, Chen Z, Yang J et al.. “Effect of KLF15-Mediated Circadian Rhythm on Myocardial Infarction: A Narrative Review.” International journal of molecular sciences (2025). PMID: 40429972 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [39]
Chaturvedi A, Gadela NV, Kalra K et al.. “Non-atherosclerotic coronary causes of myocardial infarction in women.” Progress in cardiovascular diseases (2025). PMID: 39880182 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [40]
Chapman AR, Taggart C, Boeddinghaus J et al.. “Type 2 myocardial infarction: challenges in diagnosis and treatment.” European heart journal (2025). PMID: 39658094 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [41]
Juhasz V, Charlier FT, Zhao TX et al.. “Targeting the adaptive immune continuum in atherosclerosis and post-MI injury.” Atherosclerosis (2024). PMID: 39546915 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [42]
Młynarska E, Czarnik W, Fularski P et al.. “From Atherosclerotic Plaque to Myocardial Infarction-The Leading Cause of Coronary Artery Occlusion.” International journal of molecular sciences (2024). PMID: 39000400 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [43]
Katz AE, Gupte T, Ganesh SK. “From Atherosclerosis to Spontaneous Coronary Artery Dissection: Defining a Clinical and Genetic Risk Spectrum for Myocardial Infarction.” Current atherosclerosis reports (2024). PMID: 38761354 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [44]
Schelemei P, Wagner E, Picard FSR et al.. “Macrophage mediators and mechanisms in cardiovascular disease.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024). PMID: 38275140 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [45]
Wang W, Huang B. “Recurrent Chest Pain Due to Spontaneous Coronary Artery Dissection Diagnosed by Optical Coherence Tomography.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 41077821 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Mori T, Aoyama H, Tanaka A et al.. “Detailed Visualization of the Dissected False Lumen Using Intravascular Ultrasound, Optical Coherence Tomography, and Angioscopy in a Young Man With Acute Myocardial Infarction Caused by Spontaneous Coronary Artery Dissection.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40437848 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Mumma BE, Kim JM, Rogers JH. “Chest Pain in the Setting of Acute Stress: A Tale of Two Women.” Clinical therapeutics (2024). PMID: 39578136 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Differential Diagnosis - [48]
Littmann L. “An unusual cause of giant T waves.” The American journal of emergency medicine (2024). PMID: 38839488 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [49]
Cojocaru PA, Țieranu ML, Piorescu MTL et al.. “Myocardical Infarction in Young Adults: Revisiting Risk Factors and Atherothrombotic Pathways.” Medicina (Kaunas, Lithuania) (2025). PMID: 41011006 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [50]
Imbesi A, Greco A, Capodanno D. “Anti-inflammatory strategies for patients with atherosclerotic coronary disease.” Expert review of cardiovascular therapy (2025). PMID: 40968010 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [51]
Sharpe EE, Rose CH, Tweet MS. “Obstetric anesthesia considerations in pregnancy-associated myocardial infarction: a focused review.” International journal of obstetric anesthesia (2024). PMID: 39227292 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [52]
McAlister C, Kang M, Alfadhel M et al.. “Thrombolysis in Spontaneous Coronary Artery Dissection-Angiographic Findings and Clinical Outcomes.” The Canadian journal of cardiology (2026). PMID: 41173456 ↗
L5OTHERCited in: Etiology and Triggering Factors - [53]
Geers J, Manral N, Park C et al.. “AI-quantified epicardial adipose tissue and prediction of future myocardial infarction in patients with cardiometabolic disease: a post-hoc analysis from the SCOT-HEART trial.” Cardiovascular diabetology (2025). PMID: 41126192 ↗
L5OTHERCited in: Etiology and Triggering Factors - [54]
Li J, Chen R, Zhou J et al.. “Effect of clonal hematopoiesis on plaque morphology and prognosis in patients with acute myocardial infarction.” Genome medicine (2025). PMID: 40855342 ↗
L5OTHERCited in: Etiology and Triggering Factors - [55]
Raphael CE, Sandoval Y, Beachey JD et al.. “Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.” Journal of the American College of Cardiology (2025). PMID: 40864006 ↗
L5OTHERCited in: Etiology and Triggering Factors - [56]
Stepanian A, Travers RJ, Tesfu A et al.. “Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.” Circulation (2025). PMID: 40762051 ↗
L5OTHERCited in: Etiology and Triggering Factors - [57]
Sun Q, Wang S, Zeng M et al.. “Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.” Circulation. Cardiovascular imaging (2025). PMID: 40755316 ↗
L5OTHERCited in: Etiology and Triggering Factors - [58]
Biccirè FG, Fabbiocchi F, Gatto L et al.. “Long-Term Prognostic Impact of OCT-Derived High-Risk Plaque Features: Extended Follow-Up of the CLIMA Study.” JACC. Cardiovascular interventions (2025). PMID: 40500004 ↗
L5OTHERCited in: Etiology and Triggering Factors - [59]
Hirose T, Fujii K, Hashimoto K et al.. “Plaque rupture and calcified nodules: major contributors to out-of-hospital cardiac arrest in acute myocardial infarction.” Cardiovascular intervention and therapeutics (2025). PMID: 40478392 ↗
L5OTHERCited in: Etiology and Triggering Factors - [60]
Xu C, Yang ML, Kho PF et al.. “Cross-Ancestry Associations of Spontaneous Coronary Artery Dissection Genetic Risk With Coronary Atherosclerosis and Migraine Headache.” Journal of the American Heart Association (2025). PMID: 40357661 ↗
L5OTHERCited in: Etiology and Triggering Factors - [61]
Giangiacomi F, Popelier B, Lochy S et al.. “OPENing a new ECLECTIC approach to NSTEMI and cardiac arrest using ECG-less coronary computed tomography angiography. Study design and rationale of two prospective clinical studies.” Cardiovascular revascularization medicine : including molecular interventions (2026). PMID: 41314866 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis - [62]
Raat W, Nees L, Vaes B. “Diagnostic accuracy of signs and symptoms in acute coronary syndrome and acute myocardial infarction.” Scandinavian journal of primary health care (2025). PMID: 39308022 ↗
L2aSR_OBSCited in: Differential Diagnosis - [63]
Kharawala A, Nagraj S, Setia G et al.. “Cardiac Critical Care of the Cardio-Obstetric Patient.” Journal of intensive care medicine (2026). PMID: 39819322 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [64]
Ricci F, Martini C, Scordo DM et al.. “ECG Patterns of Occlusion Myocardial Infarction: A Narrative Review.” Annals of emergency medicine (2025). PMID: 39818676 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [65]
Gamboa S, Shenvi C. “The great imitator: Hyperkalemia presenting with paralysis and ST segment elevations.” The American journal of emergency medicine (2026). PMID: 41274182 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [66]
Di Leo M, Vasumini N, Maida A et al.. “Cardiac magnetic resonance imaging in myocardial infarction with non-obstructive coronary arteries (MINOCA): current and evolving perspectives.” Expert review of cardiovascular therapy (2025). PMID: 41103008 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [67]
Ceriani E, Berra S, Agozzino F et al.. “ST-segment elevation in acute pericarditis and myocardial involvement: electrocardiographic and clinical profiling.” Open heart (2026). PMID: 41850763 ↗
L5OTHERCited in: Differential Diagnosis - [68]
Airaksinen KEJ, Teppo K, Vasankari T et al.. “Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41757465 ↗
L5OTHERCited in: Differential Diagnosis - [69]
Zhou Y, Chen C, Li J et al.. “Identification and Validation of Differentially Expressed mRNAs From Peripheral Leukocytes for Acute Stanford Type A Aortic Dissection.” Journal of the American Heart Association (2025). PMID: 41378480 ↗
L5OTHERCited in: Differential Diagnosis - [70]
Li L, Liu Y, Wu Y et al.. “Comparison of the cardiac troponin I-cardiac troponin T-troponin C complex and cardiac troponin I and T in distinguishing myocardial infarction using a single sample at presentation.” Clinical chemistry and laboratory medicine (2026). PMID: 41213158 ↗
L5OTHERCited in: Differential Diagnosis - [71]
Andreß S, Melnic R, Christow H et al.. “Right-sided cardiogenic shock from acute pulmonary tumor thrombotic microangiopathy: a rare but deadly cardio-oncologic and metabolic emergency.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 40954305 ↗
L5OTHERCited in: Differential Diagnosis - [72]
Zhou P, Zhang J, Wu X et al.. “Differential diagnosis of acute myocardial infarction based on plasma Exosomal MicroRNA.” International journal of legal medicine (2026). PMID: 40850945 ↗
L5OTHERCited in: Differential Diagnosis - [73]
Snavely A, Jackson L, Hunter CJ et al.. “Differentiating Type 1 and Type 2 myocardial infarction using a machine learning algorithm and biomarkers.” The American journal of emergency medicine (2025). PMID: 40834835 ↗
L5OTHERCited in: Differential Diagnosis - [74]
Du Z, Hu H, Shen C et al.. “Right Ventricular Strain as a Key Feature in Interpretable Machine Learning for Identification of Takotsubo Syndrome: A Multicenter CMR-based Study.” Academic radiology (2025). PMID: 40404506 ↗
L5OTHERCited in: Differential Diagnosis - [75]
Sax DR, Warton EM, Mark DG et al.. “Emergency Department Triage Accuracy and Delays in Care for High-Risk Conditions.” JAMA network open (2025). PMID: 40314952 ↗
L5OTHERCited in: Differential Diagnosis - [76]
Yildiz M, Pico M, Henry TD et al.. “Sex Differences in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Nonobstructive Coronary Arteries.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 39906977 ↗
L5OTHERCited in: Differential Diagnosis - [77]
Wang L, Wu H, Wu C et al.. “A deep-learning system integrating electrocardiograms and laboratory indicators for diagnosing acute aortic dissection and acute myocardial infarction.” International journal of cardiology (2025). PMID: 39880045 ↗
L5OTHERCited in: Differential Diagnosis - [78]
Li L, Liu Y, Katrukha IA et al.. “Characterization of Cardiac Troponin Fragment Composition Reveals Potential for Differentiating Etiologies of Myocardial Injury.” Clinical chemistry (2025). PMID: 39697116 ↗
L5OTHERCited in: Differential Diagnosis - [79]
Araoz PA, Gadam S, Bhanushali AK et al.. “Triple Rule Out CT in the Emergency Department: Clinical Risk and Outcomes (Triple Rule Out in the Emergency Department).” Academic radiology (2025). PMID: 39658473 ↗
L5OTHERCited in: Differential Diagnosis - [80]
Airaksinen JKE, Tuominen T, Paana T et al.. “Novel troponin fragmentation assay to discriminate between Takotsubo syndrome and acute myocardial infarction.” European heart journal. Acute cardiovascular care (2024). PMID: 39422200 ↗
L5OTHERCited in: Differential Diagnosis - [81]
Son JH, Park JK, Bang JH et al.. “Exosomal miRNAs Differentiate Chronic Total Occlusion from Acute Myocardial Infarction.” International journal of molecular sciences (2024). PMID: 39337705 ↗
L5OTHERCited in: Differential Diagnosis - [82]
Seitz A, Dicpinigaitis AJ, Zhang C et al.. “Ischemic events are infrequent in patients with ovarian hyperstimulation syndrome.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2025). PMID: 39321946 ↗
L5OTHERCited in: Differential Diagnosis - [83]
Yakovlev S, Gvozdeva A. “Left Ventricular Pericardial Strangulation: A Diagnostic Challenge in Acute Coronary Syndrome.” Methodist DeBakey cardiovascular journal (2026). PMID: 41725857 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [84]
Bui-Thi HD, Vu VH, Nguyen KD et al.. “Successful management of protracted anaphylaxis-induced severe acute respiratory distress syndrome masquerading as non-ST elevation myocardial infarction: a rare case report.” BMC cardiovascular disorders (2026). PMID: 41606487 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [85]
Dewi IP, Damayanti KR, Anggitama AM et al.. “Tackling the ST elevation in leptospirosis: A double-edged sword between bleeding and thrombosis - A case report.” Narra J (2025). PMID: 40951499 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [86]
Lacaita PG, Feuchtner GM. “Ruptured coronary aneurysm with fatal bleeding: a tricky differential diagnosis.” The international journal of cardiovascular imaging (2025). PMID: 40261595 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [87]
Ying HL, Zhao H, Zhang C et al.. “Pitfalls of computed tomography angiography examination in veno-arterial extracorporeal membrane oxygenation patients: a case report of a patient with cardiac rupture.” Journal of cardiothoracic surgery (2024). PMID: 39736763 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [88]
Raizner AE. “Myocardial Infarction with Normal Coronary Arteries.” Methodist DeBakey cardiovascular journal (2024). PMID: 39525371 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [89]
Gao S, An R, Wang C. “Tracheopericardial fistula in lung cancer masquerading as acute myocardial infarction: a case report.” BMC pulmonary medicine (2024). PMID: 39449137 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [90]
Haberman D, Verma B, Abusnina W et al.. “Low- Versus High-capacity Impella for CS After AMI: A Systematic Review and Pooled Data Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41507087 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [91]
Parlow S, Jung RG, Almoosawy SA et al.. “Prognostic Factors Among Patients Receiving Microaxial Flow Pump for Acute Myocardial Infarction-Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Critical care medicine (2026). PMID: 41504526 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [92]
Scquizzato T, Grunau B, Fernando SM et al.. “Temporary mechanical circulatory support after return of spontaneous circulation following cardiac arrest: a systematic review and meta-analysis.” Resuscitation (2025). PMID: 41232590 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [93]
Obradovic D, Schulz L, Loncar G et al.. “Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.” ESC heart failure (2026). PMID: 41711227 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [94]
Sørensen R, Møller JE, Vandenbriele C et al.. “Bleeding in Patients With Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41672689 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [95]
Jensen LO, Beske RP, Eiskjær H et al.. “Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.” Circulation. Cardiovascular interventions (2026). PMID: 41521915 ↗
L1bRCTCited in: Supportive Care and Complication Management - [96]
Kim MC, Ahn JH, Hyun DY et al.. “Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.” European heart journal (2026). PMID: 41493330 ↗
L1bRCTCited in: Supportive Care and Complication Management - [97]
Mangner N, Beske RP, Hassager C et al.. “Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.” Journal of the American College of Cardiology (2026). PMID: 41222528 ↗
L1bRCTCited in: Supportive Care and Complication Management - [98]
Nijveldt R, Maeng M, Beijnink CWH et al.. “Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41159879 ↗
L1bRCTCited in: Supportive Care and Complication Management - [99]
Laborante R, Paglianiti DA, Elia S et al.. “Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials.” ESC heart failure (2026). PMID: 41712413 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [100]
Sheng Z, Chen B. “Differences in the characteristics and outcomes of STEMI versus NSTEMI cardiogenic shock: A systematic review and meta-analysis.” Medicine (2025). PMID: 41189239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [101]
Deng L, Gao Y, Pan L et al.. “Free Triiodothyronine as a Biomarker for Ventricular Arrhythmia Following Myocardial Infarction: A Multicenter Prospective Cohort Study.” Clinical interventions in aging (2026). PMID: 41867325 ↗
L2bCOHORTCited in: Supportive Care and Complication Management, Special Populations - [102]
Israeli Hadar Y, Haim M, Tsaban G et al.. “Impact of late ventricular fibrillation on postdischarge 1-year mortality of patients presenting with acute myocardial infarction: a nationwide retrospective study.” BMJ open (2025). PMID: 41469077 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [103]
Kloosterman M, Smits KC, Stoks J et al.. “Computer-aided characterization of the arrhythmogenic substrate after myocardial infarction.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 41512109 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Thiele H, Hassager C. “Cardiogenic Shock.” The New England journal of medicine (2026). PMID: 41467651 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [105]
Marcos-Garcés V, Bertolín-Boronat C, Merenciano-González H et al.. “Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation.” International journal of molecular sciences (2025). PMID: 41303447 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [106]
Spaeth LD, Rahim M, Kochar A et al.. “Cardiogenic Shock and Temporary Mechanical Circulatory Support.” The Medical clinics of North America (2025). PMID: 41136064 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [107]
Boettger P, Preusse-Sondermann H, Sedighi J et al.. “Acute kidney injury as a prognostic determinant in cardiogenic shock: a cohort study.” Clinical and experimental nephrology (2026). PMID: 41225284 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [108]
Hassan AM, Aziz F, Tripolt NJ et al.. “Carbohydrate antigen 125 (CA125) following acute myocardial infarction: effects of empagliflozin and association with heart failure readouts in the EMMY trial.” Scientific reports (2025). PMID: 41430429 ↗
L1bRCTCited in: Supportive Care and Complication Management - [109]
Filipescu R, Collins SP, Radu RI et al.. “Therapeutic Advances in the Management of Cardiogenic Shock.” American journal of therapeutics (Unknown). PMID: 41543923 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [110]
Adi A, Jain R, Guru S et al.. “Antimicrobial Use in Acute Myocardial Infarction-Related Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41904804 ↗
L5OTHERCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [111]
Feng R, Hu L, Zhu Y et al.. “Association between TyG-related indices and in-hospital acute heart failure in patients with acute myocardial infarction after emergency percutaneous coronary intervention.” Frontiers in endocrinology (2026). PMID: 41869030 ↗
L5OTHERCited in: Supportive Care and Complication Management - [112]
Smyth D, Zhang L, Al-Khalaf M et al.. “Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction.” Nature cardiovascular research (2026). PMID: 41820671 ↗
L5OTHERCited in: Supportive Care and Complication Management - [113]
Wei Q, Zhou H, Sun J et al.. “SLC31A1 knockdown mitigates post-MI heart failure via regulation of copper metabolism.” Frontiers in immunology (2026). PMID: 41808820 ↗
L5OTHERCited in: Supportive Care and Complication Management - [114]
Wybraniec MT, Sufryd A, Cichoń M et al.. “Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.” ESC heart failure (2026). PMID: 41746839 ↗
L5OTHERCited in: Supportive Care and Complication Management - [115]
Han T, Wen X, Guo Y et al.. “E3 ubiquitin ligase TRIM21-mediated K48-linked ubiquitination of ALDH2 rs671 mutant promotes adverse cardiac remodeling.” JCI insight (2026). PMID: 41734032 ↗
L5OTHERCited in: Supportive Care and Complication Management - [116]
Cheng M, Li L, Huang X et al.. “Linggui Zhugan Decoction mitigates post-myocardial infarction heart failure through modulation of cardiomyocyte F-actin cytoskeletal organization.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41655544 ↗
L5OTHERCited in: Supportive Care and Complication Management - [117]
Zhou MM, Xu L, Huang DZ et al.. “KCNQ2 downregulation in left stellate ganglion neurons exacerbates malignant ventricular arrhythmias after myocardial infarction.” Journal of molecular and cellular cardiology (2026). PMID: 41654290 ↗
L5OTHERCited in: Supportive Care and Complication Management - [118]
Semedzhieva NE, Tsakova A, Lozanova V et al.. “17β-Estradiol Does Not Designate Non-Sex-Specific Early Ventricular Arrhythmia in Acute Myocardial Infarction, in Contrast to C-Reactive Protein.” International journal of molecular sciences (2026). PMID: 41596617 ↗
L5OTHERCited in: Supportive Care and Complication Management - [119]
Chiotis S, Giannopoulos G, Boulmpou A et al.. “Association of common risk factors with major adverse cardiac events and mortality in patients with MINOCA: A systematic review and meta-analysis.” International journal of cardiology (2026). PMID: 41655606 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [120]
Shen X, Zhang H, Li Z et al.. “Post-PCI Global QFR and Long-Term Outcomes in ACS: Findings From the FAVOR III China Trial.” JACC. Cardiovascular interventions (2026). PMID: 41986039 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [121]
Passo BD, Tonet E, Lanzilotti V et al.. “Consistent benefit of physiology-guided complete revascularization across the spectrum of frailty in older patients with myocardial infarction: a prespecified analysis of the FIRE trial.” Age and ageing (2026). PMID: 41965249 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [122]
Choi KH, Kang D, Kim W et al.. “Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41910427 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [123]
Sans-Roselló J, Fernández-Peregrina E, Kuku KO et al.. “Timing of cardiogenic shock and clinical outcomes in takotsubo syndrome: A multicenter cohort study.” International journal of cardiology (2026). PMID: 41765143 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [124]
Madhavan MV, Gregson J, Redfors B et al.. “Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.” Circulation (2026). PMID: 41664927 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [125]
Liu Y, Liu X, Sun D et al.. “Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41656976 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [126]
Heuts S, Pustjens TF, Lux Á et al.. “Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI: A Bayesian re-analysis of the SLIM trial.” American heart journal (2026). PMID: 41654213 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [127]
Zhao P, Li ZX, Jiang EL et al.. “Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: A national cohort study.” Cancer letters (2026). PMID: 41628833 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [128]
Huang DS, Fang CY, Hsueh SK et al.. “Predictors of Clinical Outcomes in Myocardial Infarction Patients Underwent Coronary Intervention With Rotational Atherectomy: A Single-Center Retrospective Study in Southern Taiwan.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41623217 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [129]
Armstrong PW, Zheng Y, Welsh RC et al.. “Primary percutaneous coronary intervention within the first hour: Insights from early-treated patients with ST-elevation myocardial infarction.” American heart journal (2026). PMID: 41619999 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [130]
Wang B, Song Y, Fan Y et al.. “Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study.” Cardiovascular therapeutics (2026). PMID: 41964389 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [131]
Zhou T, Yang K, Yang Y et al.. “Complete Blood Count-Derived Inflammation Indices to Predict 3-Year All-Cause Mortality in Patients With Diabetes and Acute Myocardial Infarction in Critical Care: Retrospective Cohort Study With Single-Center External Validation.” JMIR medical informatics (2026). PMID: 41818746 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [132]
Spadafora L, Bernardi M, Biondi-Zoccai G et al.. “GRACE score for risk stratification and completeness of revascularization in older patients with myocardial infarction.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 41860766 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [133]
Zhao X, Chen R, Li J et al.. “Utility of Novel Lipid Parameters for Risk Stratification in Patients with Diabetes and STEMI-from a Prospective Study.” Vascular health and risk management (2026). PMID: 41877706 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [134]
Nyanga AF, Mohamed J, Msunza M et al.. “Performance of the Grace ACS Risk Score in Predicting in-Hospital and Six-Month Mortality in Patients with ACS: A Single Center Retrospective Cohort Study.” Vascular health and risk management (2026). PMID: 41736925 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [135]
Sundh J, Parker WAE, Oldgren J et al.. “Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.” International journal of chronic obstructive pulmonary disease (2026). PMID: 41947782 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes, Special Populations - [136]
Yarahmadi P, Hedlin H, Bates S et al.. “Survival After the First Myocardial Infarction in Older Women: A Prospective Cohort Analysis From the WHI.” Journal of the American Heart Association (2026). PMID: 41848053 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [137]
Dahiya G, Bohman JK, Tonna JE et al.. “Acid-Base Status During Venoarterial Extracorporeal Membrane Oxygenator Support in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41823232 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [138]
Elbadawi A, Chen A, Wojdyla D et al.. “Contemporary Trends, Characteristics, and Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Stent Thrombosis.” JACC. Cardiovascular interventions (2026). PMID: 41813273 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [139]
Kwon Y, Kim N, Kim DH et al.. “Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.” Journal of the American Heart Association (2026). PMID: 41757462 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [140]
Sharma M, Dong Q, Hirano T et al.. “Asundexian for Secondary Stroke Prevention.” The New England journal of medicine (2026). PMID: 41985132 ↗
L1bRCTCited in: Special Populations - [141]
Delewi R, Aarts HM, Broeze GM et al.. “Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.” Lancet (London, England) (2026). PMID: 41921523 ↗
L1bRCTCited in: Special Populations - [142]
Kang J, Park S, Yang HM et al.. “Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.” Lancet (London, England) (2026). PMID: 41921522 ↗
L1bRCTCited in: Special Populations - [143]
Marcadenti A, Bersch-Ferreira AC, Vieira Machado RH et al.. “Supplementation with mixed nuts does not improve inflammatory biomarkers or dietary inflammatory potential in post-myocardial infarction: a secondary analysis of the DICA-NUTS trial.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41856832 ↗
L1bRCTCited in: Special Populations - [144]
Sundqvist MO, Wärme J, Hjort M et al.. “Helicobacter pylori, Inflammation, and Long-Term Outcome in Patients With Acute Myocardial Infarction: A Prospective Cohort Study.” Helicobacter (2026). PMID: 41834132 ↗
L2bCOHORTCited in: Special Populations - [145]
Asadi N, Azarbarzin M, Salmani F. “The effect of early mobilization program on changes in hemodynamic symptoms in patients with acute myocardial infarction.” Journal of bodywork and movement therapies (2026). PMID: 41927220 ↗
L1bRCTCited in: Special Populations - [146]
Wang H, Chou E, Robinson RD et al.. “Federated Meta-Analysis of HEART Score Performance for Emergency Department Chest Pain.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41943236 ↗
L2aSR_OBSCited in: Special Populations - [147]
Turchin A, Shubina M, Morrison FJ et al.. “Cumulative excess weight exposure over time and cardiovascular risk: A prospective cohort study.” PloS one (2026). PMID: 41950162 ↗
L2bCOHORTCited in: Special Populations - [148]
Nesova A, Vorobeva D, Ryabov V. “Impact of the risk-treatment paradox on in-hospital and long-term outcomes in patients with very high-risk non-ST-elevation acute coronary syndrome.” The Indian journal of medical research (2026). PMID: 41934433 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [149]
Shen YC, Sarkar N, Hsia RY. “Community-Level Procedure Volume and Patient Health Profiles Following PCI-Capable Facility Openings.” JAMA network open (2026). PMID: 41910975 ↗
L5OTHERCited in: Special Populations - [150]
Cars T, Gustafsson S, Chan Q et al.. “Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction.” Pharmacoepidemiology and drug safety (2026). PMID: 41902372 ↗
L5OTHERCited in: Special Populations - [151]
Chen Y, Chang A, Cheng F et al.. “A nomogram for predicting in-hospital death in a multinational cohort of patients with takotsubo syndrome.” European journal of clinical investigation (2026). PMID: 41888991 ↗
L5OTHERCited in: Special Populations - [152]
Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.” Cardiovascular intervention and therapeutics (2026). PMID: 41749019 ↗
L1cGUIDELINECited in: Guidelines and Resources - [153]
Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2025). PMID: 40014670 ↗
L1cGUIDELINECited in: Guidelines and Resources - [154]
Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.” Cardiovascular intervention and therapeutics (2024). PMID: 39302533 ↗
L1cGUIDELINECited in: Guidelines and Resources - [155]
Mahmud E, Dauerman HL, Welt FGP et al.. “Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).” Journal of the American College of Cardiology (2020). PMID: 32330544 ↗
L1cGUIDELINECited in: Guidelines and Resources - [156]
Baran DA, Grines CL, Bailey S et al.. “SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019). PMID: 31104355 ↗
L1cGUIDELINECited in: Guidelines and Resources - [157]
Charpentier S, Chenevier-Gobeaux C. “[2015 ESC guidelines: 1-hour rule-out and rule-in of acute myocardial infarction with high-sensitive troponin T].” Presse medicale (Paris, France : 1983) (2016). PMID: 27374265 ↗
L1cGUIDELINECited in: Guidelines and Resources - [158]
Beygui F, Castren M, Brunetti ND et al.. “Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC.” European heart journal. Acute cardiovascular care (2020). PMID: 26315695 ↗
L1cGUIDELINECited in: Guidelines and Resources - [159]
Qaseem A, Fihn SD, Williams S et al.. “Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons.” Annals of internal medicine (2012). PMID: 23165664 ↗
L1cGUIDELINECited in: Guidelines and Resources - [160]
George JC, Dangas GD. “2009 Focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology.” JACC. Cardiovascular interventions (2010). PMID: 20170887 ↗
L1cGUIDELINECited in: Guidelines and Resources - [161]
Pollack CV, Antman EM, Hollander JE. “2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.” Annals of emergency medicine (2008). PMID: 18519158 ↗
L1cGUIDELINECited in: Guidelines and Resources - [162]
Hesse B, Lindhardt TB, Acampa W et al.. “EANM/ESC guidelines for radionuclide imaging of cardiac function.” European journal of nuclear medicine and molecular imaging (2008). PMID: 18224320 ↗
L1cGUIDELINECited in: Guidelines and Resources - [163]
Campbell-Scherer DL, Green LA. “ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.” American family physician (2009). PMID: 19530638 ↗
L1cGUIDELINECited in: Guidelines and Resources - [164]
Thiele H, Desch S, de Waha S. “[Acute myocardial infarction in patients with ST-segment elevation myocardial infarction : ESC guidelines 2017].” Herz (2017). PMID: 29119223 ↗
L1cGUIDELINECited in: Guidelines and Resources - [165]
Schäfer A, Bauersachs J. “[Focused update on dual antiplatelet treatment : ESC guidelines 2017].” Herz (2017). PMID: 29043405 ↗
L1cGUIDELINECited in: Guidelines and Resources - [166]
Pollack CV, Hollander JE, Chen AY et al.. “Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative.” Critical pathways in cardiology (2009). PMID: 19258835 ↗
L1cGUIDELINECited in: Guidelines and Resources - [167]
. “[Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Part VI].” Kardiologiia (2008). PMID: 18991825 ↗
L1cGUIDELINECited in: Guidelines and Resources - [168]
Massberg S, Polzin A. “[Update ESC-Guideline 2017: Dual Antiplatelet Therapy].” Deutsche medizinische Wochenschrift (1946) (2018). PMID: 30060279 ↗
L1cGUIDELINECited in: Guidelines and Resources - [169]
Hochholzer W, Neumann FJ. “[The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].” Deutsche medizinische Wochenschrift (1946) (2016). PMID: 27254627 ↗
L1cGUIDELINECited in: Guidelines and Resources - [170]
Pepi M, Evangelista A, Nihoyannopoulos P et al.. “Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC).” European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology (2010). PMID: 20702884 ↗
L1cGUIDELINECited in: Guidelines and Resources - [171]
. “API expert consensus document on management of ischemic heart disease.” The Journal of the Association of Physicians of India (2006). PMID: 16909697 ↗
L1cGUIDELINECited in: Guidelines and Resources - [172]
Mahler SA, Ashburn NP, Villenthi A et al.. “Validation of a 0/2-Hour Point-Of-Care High Sensitivity Troponin Algorithm: A Multisite US Study.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 42470147 ↗
L2bCited in: Definition, Synonyms, and Classification - [173]
Garrouste V, Guerineau A, Guenezan J et al.. “External Validation of the SCARE Score for Predicting Acute Myocardial Infarction in Patients Calling Emergency Medical Communication Centers: A Prospective Multicenter Study.” Prehospital emergency care (2026). PMID: 42213793 ↗
L2bCited in: Definition, Synonyms, and Classification - [174]
Alasmary MY, Almalki MJ, Almalki FH et al.. “Interleukin-6 Inhibition for Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.” Saudi medical journal (2026). PMID: 42293710 ↗
L1aCited in: Definition, Synonyms, and Classification - [175]
Shlyakhover VE, Rozenbaum Z, Bruoha S. “Superimposed Takotsubo syndrome and acute myocardial infarction: a systematic review and pooled analysis of published cases.” International journal of cardiology. Heart & vasculature (2026). PMID: 42327959 ↗
L2aCited in: Definition, Synonyms, and Classification - [176]
Gupta MD, Kunal S, Girish MP et al.. “Comparison of ASCVD Risk Prediction Models in STEMI: Insights From a South Asian Cohort.” JACC. Asia (2026). PMID: 42470426 ↗
L3bCited in: Definition, Synonyms, and Classification - [177]
Mallol-Simmonds M, Rojas CG, Cañete Palta I et al.. “Depressive symptoms and health-related quality of life following acute myocardial infarction.” Frontiers in cardiovascular medicine (2026). PMID: 42445537 ↗
L3bCited in: Definition, Synonyms, and Classification - [178]
Gao S, Wang Y, Wang J et al.. “Elevated angiography-derived microvascular resistance and HbA1c levels jointly predict adverse outcomes in patients with diabetic STEMI: a multicenter retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42440617 ↗
L3bCited in: Definition, Synonyms, and Classification - [179]
Li Y, Wang Y, Lu P et al.. “Joint effects of severe obesity and inflammation on mortality in critically ill non-ST-segment elevation myocardial infarction patients: a cohort study with external validation.” Frontiers in endocrinology (2026). PMID: 42422429 ↗
L4Cited in: Definition, Synonyms, and Classification - [180]
Yu H, Qi S, Tian G. “The predictive value of NT-proBNP/ALB ratio for in-hospital pericardial effusion in young acute myocardial infarction patients.” Frontiers in cardiovascular medicine (2026). PMID: 42422178 ↗
L3bCited in: Definition, Synonyms, and Classification - [181]
Wrenn JO, Behrens M, Hershey MS et al.. “Large Language Model Summarization of Physician-to-Physician Calls for Interhospital Transfer of Patients With ST-Elevation Myocardial Infarction: Observational Study.” Journal of medical Internet research (2026). PMID: 42348906 ↗
L3bCited in: Definition, Synonyms, and Classification - [182]
Schwab M, Pamminger M, Kremser C et al.. “Association of Deep Learning-based Myocardial Infarction Size Quantification in Cardiac MRI with Cardiac Biomarker Levels.” Radiology. Cardiothoracic imaging (2026). PMID: 42347575 ↗
L3bCited in: Definition, Synonyms, and Classification - [183]
Yang Z, Liu Z, Xu Y et al.. “Serum LRG1 as a non-invasive biomarker for identifying complex coronary anatomy in pre-angiography risk stratification.” Frontiers in cardiovascular medicine (2026). PMID: 42338730 ↗
L3bCited in: Definition, Synonyms, and Classification - [184]
Wong HJ, Teo FJJ, Yau CE et al.. “Prognosis of patients with ST-elevation myocardial infarction presenting to the emergency department without chest pain: a retrospective nationwide cohort study.” Heart (British Cardiac Society) (2026). PMID: 42315345 ↗
L3bCited in: Definition, Synonyms, and Classification - [185]
Ninla-Aesong P, Sanakus S, Phonphet C et al.. “CBC-Derived Inflammatory Indices and Myocardial Injury Severity at Presentation in Acute Myocardial Infarction: Association and Discriminative Performance.” Journal of clinical medicine (2026). PMID: 42279258 ↗
L3bCited in: Definition, Synonyms, and Classification - [186]
Jiang H, Zhao Y, Zhao Y et al.. “Association between hemoglobin glycation index and all-cause mortality in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.” Frontiers in endocrinology (2026). PMID: 42267308 ↗
L3bCited in: Definition, Synonyms, and Classification - [187]
Chen BH, Li SL, Xiang JY et al.. “AI-based Histologic Heterogeneity of Microvascular Obstruction at Cardiac MRI for Predicting MACEs: A Multicenter Study.” Radiology (2026). PMID: 42227866 ↗
L3bCited in: Definition, Synonyms, and Classification - [188]
Mantilla Pérez B, Hurtado-Ortiz A, López J et al.. “Health-related quality of life after acute myocardial infarction and one-year clinical outcomes: A prospective cohort study.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42472246 ↗
L2bCited in: Definition, Synonyms, and Classification - [189]
Kaya AF, Ayhan G, Can V et al.. “An Inflammation-renal composite approach to predict contrast-induced nephropathy in acute myocardial infarction.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42434342 ↗
L2bCited in: Definition, Synonyms, and Classification - [190]
Stipčević M, Jurin I, Knežević Praveček M et al.. “Psychological Burden and Psychosocial Stress in Younger and Middle-Aged Women with Prior Myocardial Infarction.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356095 ↗
L2bCited in: Definition, Synonyms, and Classification - [191]
Wang F, Ning M, Liu Y. “Prognostic value of X-box binding protein 1 and phospholipase A2 in myocardial injury after ST-segment elevation myocardial infarction: a prospective observational study.” Journal of cardiothoracic surgery (2026). PMID: 42289708 ↗
L2bCited in: Definition, Synonyms, and Classification - [192]
Gorog DA. “New approaches to preventing venous thromboembolism, prognostication in stroke and myocardial infarction, and antiplatelet therapy after spontaneous coronary artery dissection.” Journal of thrombosis and thrombolysis (2025). PMID: 40569553 ↗
L1bCited in: Etiology and Triggering Factors - [193]
Li J, Chen R, Zhao X et al.. “Circulating and Regional Matrix Gla Protein Indicating Plaque Calcification and Prognosis of Patients with ST-Segment Elevation Myocardial Infarction.” Thrombosis and haemostasis (2025). PMID: 40409299 ↗
L2bCited in: Etiology and Triggering Factors - [194]
Maaniitty T, Bär S, Bax JJ et al.. “Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.” Circulation. Cardiovascular imaging (2026). PMID: 41937634 ↗
L3bCited in: Etiology and Triggering Factors - [195]
Liu X, Wang B, Hao W et al.. “Association of Obstructive Sleep Apnea and Nocturnal Hypoxemia With the Circadian Rhythm of Myocardial Infarction.” Journal of the American Heart Association (2025). PMID: 39868516 ↗
L3bCited in: Etiology and Triggering Factors - [196]
Lu ZF, Cao Y, Abrol S et al.. “Predictive value of plaque features quantified by coronary CT angiography for periprocedural myocardial infarction in Non-ST-Segment elevation acute coronary syndrome.” The international journal of cardiovascular imaging (2025). PMID: 41233700 ↗
L2bCited in: Etiology and Triggering Factors - [197]
Chaturvedi A, Garcia-Garcia HM, Cellamare M et al.. “Outcomes of Primary Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction With Versus Without Spontaneous Coronary Artery Dissection.” The American journal of cardiology (2025). PMID: 40107333 ↗
L2bCited in: Etiology and Triggering Factors - [198]
Wang S, Luo X, Hu S et al.. “Plaque erosion risk and JAK2 V617F variant.” European heart journal (2025). PMID: 40053703 ↗
L3bCited in: Etiology and Triggering Factors - [199]
Hikino K, Koyama S, Ito K et al.. “RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction.” JAMA cardiology (2024). PMID: 38888930 ↗
L3bCited in: Etiology and Triggering Factors - [200]
Murphy BM, Rogerson MC, Iismaa SE et al.. “Attitudes to and Attendance at Cardiac Rehabilitation After Spontaneous Coronary Artery Dissection.” Journal of cardiopulmonary rehabilitation and prevention (2025). PMID: 40257821 ↗
L3bCited in: Etiology and Triggering Factors - [201]
Kaddoura R, Mahmoud YA, Nasrallah D et al.. “Impact of cardiogenic shock on outcomes in patients with spontaneous coronary artery dissection: a systematic review and meta-analysis.” Panminerva medica (2026). PMID: 41925733 ↗
L2aCited in: Etiology and Triggering Factors - [202]
Budassi S, Biccirè FG, Gatto L et al.. “Independent role of atherosclerotic plaque composition and extension in predicting the risk of cardiac events: a CLIMA substudy.” The international journal of cardiovascular imaging (2024). PMID: 39432135 ↗
L3bCited in: Etiology and Triggering Factors - [203]
Schönbeck H, Björkelund A, Møller ES et al.. “A missed diagnosis of acute aortic syndrome is associated with ischaemic ECG changes and an initial suspicion of myocardial infarction: a retrospective observational study.” BMC emergency medicine (2025). PMID: 41315990 ↗
L3bCited in: Differential Diagnosis - [204]
Lindahl B, Thurston AJ, Tew YY et al.. “Change in cardiac troponin T to differentiate acute from chronic myocardial injury in the Emergency Department.” Clinical biochemistry (2025). PMID: 41241321 ↗
L2bCited in: Differential Diagnosis - [205]
Recchioni T, Manzi G, Caputo A et al.. “Sodium nitroprusside: A comprehensive systematic review of its role across various clinical settings.” Vascular pharmacology (2026). PMID: 41903872 ↗
L1aCited in: Differential Diagnosis - [206]
Pernigo M, Berti M, Renga EM et al.. “Enhancing echocardiographic diagnosis of typical Takotsubo syndrome: validation of IAR and ILAR indexes.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 42349394 ↗
L3bCited in: Differential Diagnosis - [207]
Lin H, Sun Q, Yao W et al.. “Fear of movement and its associated psychosocial factors in patients with acute cardiovascular disease: a retrospective cohort study.” BMC cardiovascular disorders (2026). PMID: 41975277 ↗
L3bCited in: Differential Diagnosis - [208]
Puchongmart C, Lorlowhakarn K, Thiravetyan B et al.. “In-hospital outcomes associated with extracorporeal membrane oxygenation in Takotsubo cardiomyopathy with cardiogenic shock: a propensity-matched analysis of a national cohort.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 41703407 ↗
L3bCited in: Differential Diagnosis - [209]
Huang Q, Zhao P, He Y et al.. “Multiparametric integration of cardiac markers in differentiating myocardial infarction with non-obstructive coronary arteries: LASSO regression.” Heart & lung : the journal of critical care (2025). PMID: 41135216 ↗
L3bCited in: Differential Diagnosis - [210]
Mele M, Mautone F, Ragnatela I et al.. “Biomarker profiles that differentiate type-1 and type 2 myocardial infarction.” Heart & lung : the journal of critical care (2025). PMID: 39752808 ↗
L3bCited in: Differential Diagnosis - [211]
Ripon RH, Zahin H, Noman AA et al.. “CDK7 as a Potential Exploratory Biomarker for Distinguishing Acute Myocardial Infarction Subtypes via DDR Pathways: Evidence From a Bangladeshi Cohort.” Clinical cardiology (2026). PMID: 42267702 ↗
L3bCited in: Differential Diagnosis - [212]
Huang M, Lin L, Fan XX et al.. “Development of a machine-learning based diagnosis procedure to distinguish aortic dissection from non-ST-elevation myocardial infarction.” BMC medical informatics and decision making (2026). PMID: 41882701 ↗
L5Cited in: Differential Diagnosis - [213]
Diercks D, Cao M, McHugh M et al.. “Evaluation and management of chest pain from cardiovascular causes in female patients.” BMJ (Clinical research ed.) (2026). PMID: 41617253 ↗
L5Cited in: Differential Diagnosis - [214]
Shen Y, Guo X, Zeng C et al.. “Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study.” Journal of the American College of Cardiology (2026). PMID: 41778949 ↗
L2bCited in: Supportive Care and Complication Management - [215]
Jøns C, Søgaard P, Smilde T et al.. “Pitfalls in the reporting of clinical events in unblinded device trials: analysing performance bias in the BIO|GUARD-MI trial.” Trials (2026). PMID: 42129909 ↗
L1bCited in: Supportive Care and Complication Management - [216]
Alasnag M, Asiri A, Alrahbi H et al.. “National Heart Center - Saudi Health Council Acute Myocardial Infarction-Related Cardiogenic Shock Consensus Document.” Saudi medical journal (2026). PMID: 42238290 ↗
L1cCited in: Supportive Care and Complication Management - [217]
Patail H, Sharma T, Chand S et al.. “The Role of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock-Part Two: Getting with the Guidelines and the Future ahead.” Interventional cardiology clinics (2026). PMID: 42209066 ↗
L1bCited in: Supportive Care and Complication Management - [218]
Franco D, Belohlavek J, Rob D et al.. “Impact of cardiac arrest in patients with cardiogenic shock due to ST-elevation myocardial infarction.” Resuscitation (2026). PMID: 42019600 ↗
L3bCited in: Supportive Care and Complication Management - [219]
Fujimoto H, Komiyama K, Kodera S et al.. “Impella in killip class IV acute myocardial infarction complicated by pulseless ventricular arrhythmia.” Cardiovascular intervention and therapeutics (2026). PMID: 41904306 ↗
L3bCited in: Supportive Care and Complication Management - [220]
Elhadad A, El Zouhayri O, Silvain J et al.. “Efficacy and Safety of Intravenous Antiplatelet Therapy in Acute Myocardial Infarction With Cardiogenic Shock.” JACC. Cardiovascular interventions (2026). PMID: 41672691 ↗
L3bCited in: Supportive Care and Complication Management - [221]
Daoulah A, M Ladna J, Arabi A et al.. “Postangiography Prediction of Renal Replacement Therapy in Acute Myocardial Infarction-Related Cardiogenic Shock: Least Absolute Shrinkage and Selection Operator Nomogram Development and Validation.” JMIR cardio (2026). PMID: 42160715 ↗
L3bCited in: Supportive Care and Complication Management - [222]
Liu T, Meng Z, Li D et al.. “The association between glycemic variability and atrial fibrillation/in-hospital mortality in white and non-white patients with acute myocardial infarction: A retrospective cohort study.” Journal of the National Medical Association (2026). PMID: 42103517 ↗
L3bCited in: Supportive Care and Complication Management - [223]
Ammoury C, Ramu SK, Rajendran J et al.. “Timing of New-Onset Atrial Fibrillation After Myocardial Infarction: Prognostic Impact and Associated Clinical Characteristics.” The American journal of cardiology (2026). PMID: 42069282 ↗
L3bCited in: Supportive Care and Complication Management - [224]
Li H, Ma Y, Su Y. “Initial intra-aortic balloon pump versus Impella support strategies and short-term outcomes in acute myocardial infarction complicated by cardiogenic shock: a MIMIC-IV cohort study.” BMC cardiovascular disorders (2026). PMID: 42032454 ↗
L4Cited in: Supportive Care and Complication Management - [225]
Todurov M, Todurov B, Mokryk I et al.. “Impact of concomitant intra-aortic balloon pump support on outcomes in patients with acute myocardial infarction-related cardiogenic shock undergoing percutaneous coronary intervention with veno-arterial ECMO: a propensity-matched analysis.” BMC cardiovascular disorders (2026). PMID: 41922989 ↗
L3bCited in: Supportive Care and Complication Management - [226]
Rubino F, Mossop H, Ripley DP et al.. “Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical Trial.” JAMA network open (2026). PMID: 42012832 ↗
L1bCited in: Prognosis and Long-term Outcomes - [227]
Ratcovich H, Holmvang L, Sadjadieh G et al.. “Percutaneous Coronary Intervention in Frail Patients Undergoing Transcatheter Aortic Valve Replacement: A NOTION-3 Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41986033 ↗
L1bCited in: Prognosis and Long-term Outcomes - [228]
Sarti A, Verardi FM, Cavazza C et al.. “Diabetes does not attenuate the benefit of physiology-guided complete revascularization in older patients with myocardial infarction.” Cardiovascular diabetology (2026). PMID: 41981421 ↗
L1bCited in: Prognosis and Long-term Outcomes - [229]
Wang Y, Zeng C, Huang YL et al.. “The association of triglyceride-glucose index with acute myocardial infarction and all-cause mortality in patients with coronary artery disease stratified by acute myocardial infarction status: a large-scale retrospective cohort study from South China.” BMJ open (2026). PMID: 42276806 ↗
L2bCited in: Prognosis and Long-term Outcomes - [230]
Miao Y, Shen L, Wang L et al.. “Echocardiographic grading for long-term mortality risk stratification after first-time ST-segment elevation myocardial infarction: a multicentre cohort study.” BMJ open (2026). PMID: 42014156 ↗
L2bCited in: Prognosis and Long-term Outcomes - [231]
Kim S, Jun HJ, Jo G et al.. “Associations of plasma level of soluble LDL receptor with cardiovascular events and mortality in a large prospective cohort study.” Lipids in health and disease (2026). PMID: 41963945 ↗
L2bCited in: Prognosis and Long-term Outcomes - [232]
Wang W, Li Q, Shu L et al.. “Association between stress hyperglycemia ratio and in-hospital mortality in acute myocardial infarction: a dose-response meta-analysis.” BMC cardiovascular disorders (2026). PMID: 42092793 ↗
L2aCited in: Prognosis and Long-term Outcomes - [233]
Zhao Y, Jiang H, Zhao Y et al.. “Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction.” Frontiers in endocrinology (2026). PMID: 42466342 ↗
L3bCited in: Prognosis and Long-term Outcomes - [234]
Guimaraes AR, Williams SE, Macmillan MT et al.. “Machine Learning Multiorgan Analysis of Coronary CT Angiography Body Composition, Myocardial Infarction, and Mortality in the SCOT-HEART Trial.” Radiology (2026). PMID: 42377128 ↗
L3bCited in: Prognosis and Long-term Outcomes - [235]
Liu H, Hu S, Zhang Y et al.. “Development and Validation of an Interpretable Machine Learning Model for Predicting 1-Year Cardiac Death After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: A Multicenter Study.” Journal of the American Heart Association (2026). PMID: 42333686 ↗
L4Cited in: Prognosis and Long-term Outcomes - [236]
Gopal A, Kamrada C, Awad A et al.. “Association of Baseline SSRI use with post-STEMI outcomes in patients with depression.” International journal of cardiology (2026). PMID: 42203004 ↗
L3bCited in: Prognosis and Long-term Outcomes - [237]
van Steenwijk MPJ, Uitbeijerse LP, Pladet LCA et al.. “Association Between Preadmission β-Blocker Use and Venoarterial Extracorporeal Membrane Oxygenation Weaning Failure in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 42179258 ↗
L3bCited in: Prognosis and Long-term Outcomes - [238]
Hosseini F, Kang M, Segal T et al.. “Impact of malnutrition on outcomes among elderly ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention.” American heart journal (2026). PMID: 42142827 ↗
L3bCited in: Prognosis and Long-term Outcomes - [239]
Lewin D, Nersesian G, Rojas SV et al.. “Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 42087324 ↗
L4Cited in: Prognosis and Long-term Outcomes - [240]
Pesce F, Dini CS, Righini FM et al.. “Optimizing cardiogenic shock outcomes: A system-based network approach.” International journal of cardiology (2026). PMID: 42082006 ↗
L3bCited in: Prognosis and Long-term Outcomes - [241]
Tian J, Wang Z, Wang Y et al.. “Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.” The New England journal of medicine (2026). PMID: 42456136 ↗
L1bCited in: Special Populations - [242]
Kharatha M, Rezaie S, Talebi SS et al.. “Effect of head and facial massage combined with aromatherapy on sleep quality and delirium in patients with acute myocardial infarction: A randomized controlled trial.” Complementary therapies in medicine (2026). PMID: 42336252 ↗
L1bCited in: Special Populations - [243]
Leissner P, Sundelin R, Rondung E et al.. “Randomized Controlled Trial of Internet-Delivered Cognitive Behavioral Therapy After Myocardial Infarction With Nonobstructive Coronary Arteries or Takotsubo Syndrome.” Journal of the American Heart Association (2026). PMID: 42294783 ↗
L1bCited in: Special Populations - [244]
Mirhosseini SA, Sadrzadeh SA, Semirani-Nezhad D et al.. “Baseline Ejection Fraction as a Modifier of Beta-Blocker Therapeutic Effects in Post-Acute Coronary Syndrome Patients With Non-Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.” Cardiovascular therapeutics (2026). PMID: 42311050 ↗
L1aCited in: Special Populations - [245]
An X, Chen Y, Wang Y et al.. “Association Between Sleep Disorders and Adverse Cardiovascular Outcomes in Patients with Chronic Obstructive Pulmonary Disease: Insights from the UK Biobank.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42306044 ↗
L2bCited in: Special Populations - [246]
Karalis DG, Richter B, Hessen S et al.. “Electronic Health Record Alerts to Improve Lipid Lowering After a Recent Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 42261954 ↗
L2bCited in: Special Populations - [247]
Wang C, Sakita FM, Prakash T et al.. “Long-Term Implementation and Effectiveness of a Quality Improvement Intervention for Myocardial Infarction in Tanzania.” Annals of global health (2026). PMID: 42404322 ↗
L3bCited in: Special Populations - [248]
Essa H, Balu A, Johnston B et al.. “Impact of new-onset atrial fibrillation on 12-month outcomes and mortality after esophagectomy.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42328848 ↗
L3bCited in: Special Populations - [249]
Emori H, Shiono Y, Yamanobe H et al.. “Incidence of periprocedural myocardial injury and clinical outcomes after rotational atherectomy vs. intravascular lithotripsy.” International journal of cardiology (2026). PMID: 42314849 ↗
L3bCited in: Special Populations - [250]
Armentaro G, Crudo G, Menichelli D et al.. “Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.” European journal of clinical investigation (2026). PMID: 42299459 ↗
L3bCited in: Special Populations - [251]
Al-Naqdi MMA, Alkhammasi MLM, Al-Naqdi BMA. “Mortality Outcome Post-MI after PCI and CABG Interventions.” Global heart (2026). PMID: 42292644 ↗
L3bCited in: Special Populations - [252]
Filev R, Bogov B, Hadjieva R et al.. “Association of Acute-Phase IL-6 and SAA with Cardiovascular Events and Mortality Six Years After COVID-19 Infection: An Observational Cohort Study.” International journal of molecular sciences (2026). PMID: 42278254 ↗
L3bCited in: Special Populations - [253]
Mokhtar WSW, Noor JM, Baharuddin MNA et al.. “Knowledge level of ECG interpretation on STEMI, its equivalents and mimics among emergency department medical officers: a single-centre study.” BMC medical education (2026). PMID: 42252427 ↗
L3bCited in: Differential Diagnosis - [254]
Chen K, Zhao S, Zou X et al.. “Efficacy and Safety of Intracoronary Mesenchymal Stem Cell Administration in ST-Segment Elevation Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.” Clinical and translational science (2026). PMID: 42499248 ↗
L1aCited in: Prognosis and Long-term Outcomes - [255]
Januzzi JL, Gibson CM, Chi G et al.. “The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI.” American heart journal (2026). PMID: 42303064 ↗
L1bCited in: Prognosis and Long-term Outcomes - [256]
Ipek R, Schaefer E, Neuenschwander M et al.. “Prognostic factors for mortality in ST-elevation myocardial infarction in individuals with diabetes: A systematic review with implications for risk stratification and therapeutic considerations.” Pharmacology & therapeutics (2026). PMID: 42471062 ↗
L2aCited in: Prognosis and Long-term Outcomes - [257]
Simioni L, Loureiro T, Faucherre Y et al.. “Impact of obesity on 1-year major adverse cardiac events after primary PCI for STEMI.” International journal of cardiology (2026). PMID: 42361987 ↗
L2bCited in: Prognosis and Long-term Outcomes - [258]
Björkbacka H, Gonçalves I, Engström G et al.. “Associations of the inflammasome-dependent cytokine IL-18 with risk of coronary heart disease.” Cardiovascular research (2026). PMID: 42334366 ↗
L2bCited in: Prognosis and Long-term Outcomes - [259]
Xiang JY, Wu J, Zhao Y et al.. “Rethinking post-infarction remodelling: identification and validation of data-driven cardiac MRI phenotypes for risk stratification.” European heart journal. Cardiovascular Imaging (2026). PMID: 42175732 ↗
L2bCited in: Prognosis and Long-term Outcomes - [260]
Nadira A, Sunita S, Alparisi BD et al.. “Association of adipokines with major adverse cardiovascular events following acute myocardial infarction: a systematic review and meta-analysis.” BMC cardiovascular disorders (2026). PMID: 42286472 ↗
L2aCited in: Prognosis and Long-term Outcomes - [261]
Zhao Y, Wu JP, Cao SY et al.. “Prognostic Value of Cardiac MRI-derived Left-to-Right Global Longitudinal Strain Ratio in ST-Elevation Myocardial Infarction.” Radiology. Cardiothoracic imaging (2026). PMID: 42593263 ↗
L3bCited in: Prognosis and Long-term Outcomes - [262]
Ilomäki J, Tan GSQ, Qin XS et al.. “Secondary prevention of myocardial infarction in people with dementia: a multi-jurisdictional retrospective cohort study in Asia, Europe and the USA.” Age and ageing (2026). PMID: 42566699 ↗
L3bCited in: Prognosis and Long-term Outcomes - [263]
Ito R, Kondo T, Kazama S et al.. “Left Ventricular Unloading With Impella Versus Intra-Aortic Balloon Pump in Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation.” Journal of the American Heart Association (2026). PMID: 42535545 ↗
L4Cited in: Prognosis and Long-term Outcomes - [264]
Li Y, Wang S, Li G et al.. “Prognostic Value of Coronary Sinus Flow and Aortic Pressure Gradient Quantified by 4D Flow CMR in AMI.” Academic radiology (2026). PMID: 42331670 ↗
L3bCited in: Prognosis and Long-term Outcomes - [265]
Wang J, Wang Y, Li Y et al.. “Prognostic Value of the Geriatric Nutritional Risk Index for Long-Term All-Cause Mortality in Older Patients with Non-ST-Segment Elevation Myocardial Infarction.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 42308667 ↗
L3bCited in: Prognosis and Long-term Outcomes - [266]
Shiyovich A, Huck DM, Cardoso R et al.. “Prognostic Value of Coronary CT Angiography Among Patients With and Without Diabetes: The Mass General Brigham CCTA registry.” Cardiovascular diabetology (2026). PMID: 42298570 ↗
L3bCited in: Prognosis and Long-term Outcomes - [267]
Khalil I, Sarker P, Ria SG et al.. “Comparative Efficacy of GLP-1 RAs Versus SGLT2 Inhibitors in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter Propensity Score-Matched Real-World Study.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42219874 ↗
L3bCited in: Prognosis and Long-term Outcomes - [268]
Ren Y, Yang H, Zhang S et al.. “Cardiovascular outcomes of SGLT2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes and a history of myocardial infarction: a systematic review and network meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 42591121 ↗
L1aCited in: Special Populations - [269]
Lopez JJ, Volleberg RHJA, Shin D et al.. “OCT-Defined Plaque Morphology and Clinical Outcomes After Percutaneous Coronary Intervention: An ILUMIEN IV Substudy.” JACC. Cardiovascular imaging (2026). PMID: 42547197 ↗
L1bCited in: Special Populations - [270]
Choi KH, Lee SH, Kim SM et al.. “SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI.” JACC. Cardiovascular interventions (2026). PMID: 42508844 ↗
L1bCited in: Special Populations - [271]
Bertolet M, Carrier FM, Glynn S et al.. “Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction: A Post Hoc Analysis of the MINT Randomized Clinical Trial.” JAMA network open (2026). PMID: 42507445 ↗
L1bCited in: Special Populations - [272]
Baharvand F, Mehran R, Di Muro FM et al.. “Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 42467386 ↗
L1bCited in: Special Populations - [273]
Yang Y, Liu L, Liang X et al.. “Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.” Frontiers in endocrinology (2026). PMID: 42630147 ↗
L2bCited in: Special Populations - [274]
Sabat Sani H, Aghaei S, Kalantari S et al.. “Empagliflozin's Effects on Carotid Ultrasound Parameters in Type 2 Diabetes Patients Post-ST-Elevation Myocardial Infarction: A Randomized Controlled Trial.” Iranian journal of medical sciences (2026). PMID: 42571075 ↗
L1bCited in: Special Populations - [275]
Wu S, Xia MH, Zhang HR et al.. “[Effects of electroacupuncture guided by the vessel-collateral theory on short-term ventricular remodeling following STEMI-PCI surgery: a randomized controlled clinical study].” Zhen ci yan jiu = Acupuncture research (2026). PMID: 42482585 ↗
L1bCited in: Special Populations - [276]
Baik M, Jeon J, Yoo J et al.. “Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke.” Neurology (2026). PMID: 42623575 ↗
L3bCited in: Special Populations - [277]
Kim HK, Kim MS, Ahn S et al.. “Smoking Behavior and Major Cardiovascular and Limb Events in Patients With Peripheral Artery Disease.” JAMA network open (2026). PMID: 42616502 ↗
L3bCited in: Special Populations - [278]
Wang S, Li J, Xie S et al.. “Association between stress hyperglycemia ratio and acute total occlusion in patients with non-ST-segment elevation myocardial infarction.” Frontiers in endocrinology (2026). PMID: 42609313 ↗
L3bCited in: Special Populations - [279]
Ibrahim O, Farina J, Pereyra Pietri M et al.. “Diagnostic accuracy of electronic medical record retrieval methods and a large language model for identifying cardiovascular events: a multisite retrospective validation study in a medical system in the United States.” BMJ open (2026). PMID: 42595369 ↗
L3bCited in: Special Populations - [280]
Kawakami S, Kawakami D, Takei M et al.. “Early Decline in Serum Haptoglobin During Impella CP Support Compared With Intra-Aortic Balloon Pump in Cardiogenic Shock: A Single-Center Observational Study.” Journal of the American Heart Association (2026). PMID: 42568059 ↗
L3bCited in: Special Populations - [281]
Bian H, Yuan B, Wu P et al.. “Interpretable mortality prediction at VA-ECMO establishment in acute myocardial infarction: A multicenter study from the CSECLS registry.” International journal of medical informatics (2026). PMID: 42561767 ↗
L3bCited in: Special Populations - [282]
Krüger N, Schneeweiss S, Wang SV. “Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.” BMJ (Clinical research ed.) (2026). PMID: 42556854 ↗
L4Cited in: Special Populations - [283]
Yi J, Xiao Q, Zhao Z. “Case report: pheochromocytoma presenting as acute ST-segment elevation myocardial infarction without coronary artery abnormalities.” Frontiers in endocrinology (2026). PMID: 42656214 ↗
L4Cited in: Differential Diagnosis - [284]
Morrissey B. “Acute urinary retention presenting as inferior pseudo-STEMI: A case report.” The American journal of emergency medicine (2026). PMID: 42330710 ↗
L4Cited in: Differential Diagnosis - [285]
Qiu M, Duan Y, Feng X et al.. “Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI: The BRIGHT-4 Trial.” Journal of the American College of Cardiology (2026). PMID: 42663356 ↗
L1bCited in: Prognosis and Long-term Outcomes - [286]
Hakeem A, Ishaq H, Ali A et al.. “Rapid Inflation-Deflation vs Pressure-Optimized Stenting During Primary PCI: The RAPID-POP Trial.” JACC. Cardiovascular interventions (2026). PMID: 42637295 ↗
L1bCited in: Prognosis and Long-term Outcomes - [287]
Kim S, Bertolet M, Chaitman BR et al.. “Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial.” American heart journal (2026). PMID: 42571785 ↗
L1bCited in: Prognosis and Long-term Outcomes - [288]
Islam U, Marquard JM, Abdul Khalek IM et al.. “10-year outcome of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction - A DANAMI-3 PRIMULTI substudy.” International journal of cardiology (2026). PMID: 42542169 ↗
L1bCited in: Prognosis and Long-term Outcomes - [289]
Santos MCF, Mamede I, Bessa R et al.. “Efficacy of sodium-glucose cotransporter 2 inhibitors after acute myocardial infarction: Are the benefits limited to patients with diabetes? A systematic review and meta-analysis.” Journal of diabetes and its complications (2026). PMID: 42659939 ↗
L1aCited in: Prognosis and Long-term Outcomes - [290]
Regmi DR, Regmi S, Upreti S et al.. “'Aspirin versus ticagrelor for the management after coronary revascularization - a systematic review and meta‑analysis of randomised trials'.” BMC cardiovascular disorders (2026). PMID: 42380776 ↗
L1aCited in: Prognosis and Long-term Outcomes - [291]
Liang H, Wang Y, Xin Y et al.. “Clinical characteristics and prognostic differences among acute heart failure phenotypes in the emergency department: a real-world study.” BMC emergency medicine (2026). PMID: 42681602 ↗
L2bCited in: Prognosis and Long-term Outcomes - [292]
Wang Z, Wang Z, Zhi X et al.. “Association between door-to-balloon time ≤60 minutes and short- and long-term outcomes in patients with ST-segment elevation myocardial infarction: a retrospective cohort study.” BMJ open (2026). PMID: 42772868 ↗
L3bCited in: Prognosis and Long-term Outcomes - [293]
Shashar S, Cohen T, Boehm Cohen L et al.. “COPD Severity and Five-Year Mortality After Acute Myocardial Infarction in Patients with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study.” Medical sciences (Basel, Switzerland) (2026). PMID: 42646620 ↗
L3bCited in: Prognosis and Long-term Outcomes - [294]
Nishino C, Nishino S, Hayashida A et al.. “Dynamic Changes and Prognostic Impact of Ischemic Mitral Regurgitation in Recurrent Myocardial Infarction.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 42486640 ↗
L3bCited in: Prognosis and Long-term Outcomes - [295]
Nowojewski A, Elizarova O, Rutgersson A et al.. “Medication Adherence Behavior Assessed Using a Digital Bottle Cap: Retrospective Cohort Study.” Journal of medical Internet research (2026). PMID: 42767628 ↗
L1bCited in: Special Populations - [296]
Kwon W, Choi KH, Park YH et al.. “Clopidogrel monotherapy versus aspirin monotherapy in females and males after percutaneous coronary intervention: a sex-stratified analysis of the SMART-CHOICE 3 trial.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2026). PMID: 42765401 ↗
L1bCited in: Special Populations - [297]
Huang J, Tu S, Huang H et al.. “Radial wall strain for residual risk stratification after percutaneous coronary intervention.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2026). PMID: 42765400 ↗
L1bCited in: Special Populations - [298]
Biscaglia S, Erriquez A, Colaiori I et al.. “Complete Revascularization Guided by Functional Coronary Angiography in STEMI.” The New England journal of medicine (2026). PMID: 42670979 ↗
L1bCited in: Special Populations - [299]
Wu T, Zhang X, Li C et al.. “Angiography-Based Index of Microcirculatory Resistance in Assessing the MVO and Infarct Size in STEMI Patients.” Clinical cardiology (2026). PMID: 42683616 ↗
L1bCited in: Special Populations - [300]
Jurin H, Hadžibegović I, Samardžić J et al.. “Serial Platelet Function-Guided Antiplatelet Modulation After STEMI: A Randomized Pilot Study.” Journal of cardiovascular pharmacology and therapeutics (2026). PMID: 42658178 ↗
L4Cited in: Special Populations - [301]
Ma L, Hu Y, Liu G et al.. “Association of Adherence to Various Dietary Patterns With Mortality Among Survivors of Myocardial Infarction: A Prospective Cohort Study.” Circulation (2026). PMID: 42639679 ↗
L2bCited in: Special Populations - [302]
Koechlin L, Boeddinghaus J, Lopez-Ayala P et al.. “Direct Comparison of the 0/1h- and 0/2h-Algorithms in Patients With Prior Coronary Artery Bypass Grafting.” Journal of the American Heart Association (2026). PMID: 42622139 ↗
L2bCited in: Special Populations - [303]
Laurenceau T, Meli U, Wang LZ et al.. “Atenolol or Bisoprolol after Myocardial Infarction without Recorded Heart Failure.” NEJM evidence (2026). PMID: 42770784 ↗
L3bCited in: Special Populations - [304]
Roy R, Abd Razak M, Mohanan S et al.. “Phenotypes of cardiogenic shock after out-of-hospital cardiac arrest: the SCAI-V classification.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2026). PMID: 42765398 ↗
L4Cited in: Special Populations - [305]
Haider A, Hagström E, Ishak D et al.. “Diabetes status, fasting glucose and HbA1c, and outcomes after myocardial infarction: a retrospective registry-based Swedish cohort study.” BMJ open (2026). PMID: 42760071 ↗
L3bCited in: Special Populations - [306]
Hesse K, Stephens J, Batty JA et al.. “P2Y12 inhibitor pre-treatment in NSTE-ACS: translating trial evidence into UK clinical practice.” Open heart (2026). PMID: 42731862 ↗
L3bCited in: Special Populations - [307]
Barman NC, Rastogi A, Radbruch A et al.. “Detection of myocardial infarction by postmortem CT combined with radiomics-based machine-learning analysis.” European radiology experimental (2026). PMID: 42726426 ↗
L3bCited in: Special Populations - [308]
Maimaitiniyazi M, Maimaitiniyazi M, Maisuti M et al.. “Factors associated with in-hospital heart failure after emergency percutaneous coronary intervention in patients with type 2 diabetes mellitus complicated by ST-segment elevation myocardial infarction: a retrospective study.” Frontiers in endocrinology (2026). PMID: 42724904 ↗
L3bCited in: Special Populations